lndc-20210530
false2021FY00010052865/30http://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602MemberP3YP7Yhttp://fasb.org/us-gaap/2021-01-31#Liabilitieshttp://fasb.org/us-gaap/2021-01-31#Liabilitieshttp://landec.com/20210530#OperatingLeaseAndFinanceLeaseCurrenthttp://landec.com/20210530#OperatingLeaseAndFinanceLeaseCurrenthttp://landec.com/20210530#OperatingLeaseAndFinanceLeaseNoncurrenthttp://landec.com/20210530#OperatingLeaseAndFinanceLeaseNoncurrent505000010052862020-06-012021-05-30iso4217:USD00010052862020-11-29xbrli:shares00010052862021-07-2600010052862021-05-3000010052862020-05-31iso4217:USDxbrli:shares00010052862018-05-282019-05-2600010052862019-05-272020-05-310001005286us-gaap:CommonStockMember2018-05-270001005286us-gaap:AdditionalPaidInCapitalMember2018-05-270001005286us-gaap:RetainedEarningsMember2018-05-270001005286us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-05-2700010052862018-05-270001005286us-gaap:CommonStockMember2018-05-282019-05-260001005286us-gaap:AdditionalPaidInCapitalMember2018-05-282019-05-260001005286us-gaap:RetainedEarningsMember2018-05-282019-05-260001005286us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-05-282019-05-260001005286us-gaap:CommonStockMember2019-05-260001005286us-gaap:AdditionalPaidInCapitalMember2019-05-260001005286us-gaap:RetainedEarningsMember2019-05-260001005286us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-05-2600010052862019-05-260001005286us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-05-260001005286srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-05-260001005286us-gaap:CommonStockMember2019-05-272020-05-310001005286us-gaap:AdditionalPaidInCapitalMember2019-05-272020-05-310001005286us-gaap:RetainedEarningsMember2019-05-272020-05-310001005286us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-05-272020-05-310001005286us-gaap:CommonStockMember2020-05-310001005286us-gaap:AdditionalPaidInCapitalMember2020-05-310001005286us-gaap:RetainedEarningsMember2020-05-310001005286us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-05-310001005286us-gaap:CommonStockMember2020-06-012021-05-300001005286us-gaap:AdditionalPaidInCapitalMember2020-06-012021-05-300001005286us-gaap:RetainedEarningsMember2020-06-012021-05-300001005286us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-012021-05-300001005286us-gaap:CommonStockMember2021-05-300001005286us-gaap:AdditionalPaidInCapitalMember2021-05-300001005286us-gaap:RetainedEarningsMember2021-05-300001005286us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-05-30xbrli:pure0001005286lndc:WindsetMember2021-05-300001005286us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberlndc:Top5CustomersMember2020-06-012021-05-300001005286us-gaap:CustomerConcentrationRiskMemberlndc:CurationFoodsMemberlndc:WalmartMemberus-gaap:SalesRevenueNetMember2020-06-012021-05-300001005286lndc:CostcoMemberus-gaap:CustomerConcentrationRiskMemberlndc:CurationFoodsMemberus-gaap:SalesRevenueNetMember2020-06-012021-05-300001005286us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberlndc:Top5CustomersMember2019-05-272020-05-310001005286us-gaap:CustomerConcentrationRiskMemberlndc:CurationFoodsMemberlndc:WalmartMemberus-gaap:SalesRevenueNetMember2019-05-272020-05-310001005286lndc:CostcoMemberus-gaap:CustomerConcentrationRiskMemberlndc:CurationFoodsMemberus-gaap:SalesRevenueNetMember2019-05-272020-05-310001005286us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberlndc:WalmartMember2020-06-012021-05-300001005286lndc:CostcoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2020-06-012021-05-300001005286us-gaap:CustomerConcentrationRiskMemberlndc:LargestCustomerMemberus-gaap:AccountsReceivableMemberlndc:LifecoreMember2020-06-012021-05-300001005286us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberlndc:WalmartMember2019-05-272020-05-310001005286lndc:CostcoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2019-05-272020-05-310001005286us-gaap:CustomerConcentrationRiskMemberlndc:LargestCustomerMemberus-gaap:AccountsReceivableMemberlndc:LifecoreMember2019-05-272020-05-310001005286us-gaap:UnbilledRevenuesMember2021-05-300001005286us-gaap:UnbilledRevenuesMember2020-05-310001005286lndc:FreshPackagedSaladsAndVegetablesMemberlndc:CurationFoodsMember2020-06-012021-05-300001005286lndc:FreshPackagedSaladsAndVegetablesMemberlndc:CurationFoodsMember2019-05-272020-05-310001005286lndc:FreshPackagedSaladsAndVegetablesMemberlndc:CurationFoodsMember2018-05-282019-05-260001005286lndc:AvocadoProductsMemberlndc:CurationFoodsMember2020-06-012021-05-300001005286lndc:AvocadoProductsMemberlndc:CurationFoodsMember2019-05-272020-05-310001005286lndc:AvocadoProductsMemberlndc:CurationFoodsMember2018-05-282019-05-260001005286lndc:TechnologyMemberlndc:CurationFoodsMember2020-06-012021-05-300001005286lndc:TechnologyMemberlndc:CurationFoodsMember2019-05-272020-05-310001005286lndc:TechnologyMemberlndc:CurationFoodsMember2018-05-282019-05-260001005286lndc:CurationFoodsMember2020-06-012021-05-300001005286lndc:CurationFoodsMember2019-05-272020-05-310001005286lndc:CurationFoodsMember2018-05-282019-05-260001005286lndc:ContractDevelopmentAndManufacturingOrganizationMemberlndc:LifecoreMember2020-06-012021-05-300001005286lndc:ContractDevelopmentAndManufacturingOrganizationMemberlndc:LifecoreMember2019-05-272020-05-310001005286lndc:ContractDevelopmentAndManufacturingOrganizationMemberlndc:LifecoreMember2018-05-282019-05-260001005286lndc:FermentationMemberlndc:LifecoreMember2020-06-012021-05-300001005286lndc:FermentationMemberlndc:LifecoreMember2019-05-272020-05-310001005286lndc:FermentationMemberlndc:LifecoreMember2018-05-282019-05-260001005286lndc:LifecoreMember2020-06-012021-05-300001005286lndc:LifecoreMember2019-05-272020-05-310001005286lndc:LifecoreMember2018-05-282019-05-260001005286lndc:WindsetMemberus-gaap:CostOfSalesMember2020-06-012021-05-300001005286lndc:WindsetMemberus-gaap:CostOfSalesMember2019-05-272020-05-310001005286lndc:WindsetMemberus-gaap:CostOfSalesMember2018-05-282019-05-260001005286lndc:WindsetMember2021-05-300001005286lndc:WindsetMember2020-05-310001005286srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2020-06-012021-05-300001005286srt:MaximumMemberus-gaap:SoftwareDevelopmentMember2020-06-012021-05-300001005286lndc:OOliveAndVinegarMember2019-05-272020-05-310001005286lndc:OOliveAndVinegarMemberus-gaap:CustomerRelationshipsMember2019-05-272020-05-310001005286lndc:OOliveAndVinegarMemberus-gaap:TrademarksMember2019-05-272020-05-310001005286lndc:YucatanFoodsLPMemberus-gaap:TrademarksMember2019-05-272020-05-310001005286lndc:YucatanFoodsLPMember2019-05-272020-05-310001005286lndc:EatSmartMemberus-gaap:TrademarksMember2019-05-272020-05-310001005286us-gaap:RestrictedStockUnitsRSUMember2020-06-012021-05-300001005286us-gaap:RestrictedStockUnitsRSUMember2019-05-272020-05-310001005286us-gaap:EmployeeStockOptionMember2020-06-012021-05-300001005286us-gaap:EmployeeStockOptionMember2019-05-272020-05-310001005286us-gaap:EmployeeStockOptionMember2018-05-282019-05-260001005286us-gaap:EmployeeStockOptionMember2021-05-300001005286us-gaap:EmployeeStockOptionMember2020-05-310001005286us-gaap:EmployeeStockOptionMember2019-05-260001005286lndc:FirstThreePercentMatchMember2020-06-012021-05-300001005286lndc:NextTwoPercentMatchMember2020-06-012021-05-300001005286lndc:RockHillSouthCarolinaDistributionFacilityMember2021-05-300001005286lndc:SaladDressingPlantOntarioCaliforniaMember2020-05-310001005286srt:MinimumMemberus-gaap:MeasurementInputLongTermRevenueGrowthRateMemberlndc:WindsetMember2020-06-012021-05-300001005286srt:MaximumMemberus-gaap:MeasurementInputLongTermRevenueGrowthRateMemberlndc:WindsetMember2020-06-012021-05-300001005286srt:MinimumMemberus-gaap:MeasurementInputLongTermRevenueGrowthRateMemberlndc:WindsetMember2019-05-272020-05-310001005286srt:MaximumMemberus-gaap:MeasurementInputLongTermRevenueGrowthRateMemberlndc:WindsetMember2019-05-272020-05-310001005286us-gaap:MeasurementInputLongTermRevenueGrowthRateMembersrt:WeightedAverageMemberlndc:WindsetMember2019-05-272020-05-310001005286srt:MinimumMemberlndc:MeasurementInputLongtermExpenseGrowthRateMemberlndc:WindsetMember2020-06-012021-05-300001005286srt:MaximumMemberlndc:MeasurementInputLongtermExpenseGrowthRateMemberlndc:WindsetMember2020-06-012021-05-300001005286lndc:MeasurementInputLongtermExpenseGrowthRateMembersrt:WeightedAverageMemberlndc:WindsetMember2020-06-012021-05-300001005286srt:MinimumMemberlndc:MeasurementInputLongtermExpenseGrowthRateMemberlndc:WindsetMember2019-05-272020-05-310001005286srt:MaximumMemberlndc:MeasurementInputLongtermExpenseGrowthRateMemberlndc:WindsetMember2019-05-272020-05-310001005286lndc:MeasurementInputLongtermExpenseGrowthRateMembersrt:WeightedAverageMemberlndc:WindsetMember2019-05-272020-05-310001005286us-gaap:MeasurementInputDiscountRateMemberlndc:WindsetMember2020-06-012021-05-300001005286us-gaap:MeasurementInputDiscountRateMemberlndc:WindsetMember2019-05-272020-05-310001005286us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-05-300001005286us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-05-300001005286us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-05-300001005286us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-05-310001005286us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-05-310001005286us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-05-310001005286lndc:WindsetInvestmentMember2020-05-310001005286lndc:WindsetInvestmentMember2020-06-012021-05-300001005286lndc:WindsetInvestmentMember2021-05-300001005286lndc:YucatanFoodsLPMember2018-12-012018-12-010001005286us-gaap:CommonStockMemberlndc:YucatanFoodsLPMember2018-12-012018-12-010001005286lndc:YucatanFoodsLPMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2018-12-012018-12-010001005286us-gaap:ShareBasedCompensationAwardTrancheTwoMemberlndc:YucatanFoodsLPMember2018-12-012018-12-01lndc:tranche0001005286lndc:YucatanFoodsLPMember2019-02-252019-05-260001005286lndc:YucatanFoodsLPMember2019-08-262019-11-240001005286lndc:YucatanFoodsLPMember2018-12-010001005286lndc:YucatanFoodsLPMemberus-gaap:TradeNamesMember2018-12-010001005286lndc:YucatanFoodsLPMemberus-gaap:CustomerRelationshipsMember2018-12-01lndc:intangibleAsset00010052862018-12-012018-12-010001005286lndc:YucatanFoodsLPMemberus-gaap:CustomerRelationshipsMember2018-12-012018-12-010001005286lndc:CurationFoodsMemberlndc:YucatanReportingUnitMember2019-05-272020-05-310001005286us-gaap:SellingGeneralAndAdministrativeExpensesMemberlndc:YucatanFoodsLPMember2018-05-282019-05-260001005286lndc:OOliveAndVinegarMember2017-03-012017-03-010001005286lndc:OOliveAndVinegarMember2017-03-010001005286lndc:CurationFoodsMemberlndc:WindsetMemberlndc:SeniorAPreferredStockMember2011-02-150001005286lndc:CurationFoodsMemberlndc:WindsetMemberlndc:SeniorAPreferredStockMember2011-02-152011-02-150001005286us-gaap:CommonStockMemberlndc:CurationFoodsMemberlndc:WindsetMember2011-02-150001005286us-gaap:CommonStockMemberlndc:CurationFoodsMemberlndc:WindsetMember2011-02-152011-02-150001005286us-gaap:CommonStockMemberlndc:CurationFoodsMemberlndc:WindsetMember2014-07-150001005286lndc:CurationFoodsMemberlndc:WindsetMemberlndc:JuniorPreferredSharesMember2014-07-150001005286lndc:WindsetMemberlndc:CurationFoodsMember2014-07-152014-07-150001005286lndc:WindsetMember2021-05-300001005286lndc:SeniorAPreferredStockMember2014-07-152014-07-150001005286lndc:CurationFoodsMemberlndc:WindsetMemberlndc:JuniorPreferredSharesMember2021-05-300001005286lndc:WindsetMember2014-07-150001005286lndc:WindsetMemberlndc:CurationFoodsMember2021-05-300001005286lndc:CurationFoodsMemberlndc:WindsetMemberlndc:SeniorAPreferredStockMember2021-05-300001005286lndc:SeniorBPreferredStockMemberlndc:CurationFoodsMemberlndc:WindsetMember2014-10-290001005286lndc:SeniorBPreferredStockMemberlndc:CurationFoodsMemberlndc:WindsetMember2014-10-292014-10-290001005286lndc:SeniorBPreferredStockMemberlndc:CurationFoodsMemberlndc:WindsetMember2019-05-260001005286lndc:WindsetMember2020-06-012021-05-300001005286lndc:WindsetMember2019-05-272020-05-310001005286lndc:WindsetMember2018-05-282019-05-260001005286us-gaap:OtherIncomeMemberlndc:WindsetMember2018-05-282019-05-260001005286us-gaap:SubsequentEventMemberlndc:CurationFoodsMemberlndc:WindsetMember2021-06-012021-06-010001005286us-gaap:LandMember2021-05-300001005286us-gaap:LandMember2020-05-310001005286srt:MinimumMemberus-gaap:BuildingMember2020-06-012021-05-300001005286srt:MaximumMemberus-gaap:BuildingMember2020-06-012021-05-300001005286us-gaap:BuildingMember2021-05-300001005286us-gaap:BuildingMember2020-05-310001005286srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2020-06-012021-05-300001005286srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2020-06-012021-05-300001005286us-gaap:LeaseholdImprovementsMember2021-05-300001005286us-gaap:LeaseholdImprovementsMember2020-05-310001005286srt:MinimumMemberlndc:ComputerCapitalizedSoftwareMachineryEquipmentAndAutoMember2020-06-012021-05-300001005286srt:MaximumMemberlndc:ComputerCapitalizedSoftwareMachineryEquipmentAndAutoMember2020-06-012021-05-300001005286lndc:ComputerCapitalizedSoftwareMachineryEquipmentAndAutoMember2021-05-300001005286lndc:ComputerCapitalizedSoftwareMachineryEquipmentAndAutoMember2020-05-310001005286us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2020-06-012021-05-300001005286srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2020-06-012021-05-300001005286us-gaap:FurnitureAndFixturesMember2021-05-300001005286us-gaap:FurnitureAndFixturesMember2020-05-310001005286us-gaap:ConstructionInProgressMember2021-05-300001005286us-gaap:ConstructionInProgressMember2020-05-310001005286lndc:SanRafaelMember2019-05-272020-05-310001005286lndc:SaladDressingPlantOntarioCaliforniaMember2019-05-272020-05-310001005286lndc:SaladDressingPlantInOntarioCaliforniaMember2020-06-012020-08-300001005286lndc:SaladDressingPlantInOntarioCaliforniaMember2020-06-012021-05-300001005286lndc:ManufacturingOperationsInHanoverPennsylvaniaMember2020-05-310001005286lndc:ManufacturingOperationsInHanoverPennsylvaniaMember2020-06-012020-08-300001005286lndc:ManufacturingOperationsInHanoverPennsylvaniaMember2020-08-312020-11-290001005286lndc:RockHillSouthCarolinaDistributionFacilityMemberus-gaap:SubsequentEventMember2021-06-092021-06-090001005286lndc:OOliveAndVinegarMember2019-05-272020-05-310001005286lndc:YucatanFoodsLPMember2019-05-272020-05-310001005286lndc:EatSmartMember2021-05-300001005286lndc:YucatanFoodsLPMember2021-05-300001005286lndc:LifecoreMember2021-05-300001005286lndc:CurationFoodsMemberlndc:EatSmartMemberus-gaap:CustomerRelationshipsMember2020-06-012021-05-300001005286lndc:CurationFoodsMemberlndc:EatSmartMemberus-gaap:CustomerRelationshipsMember2021-05-300001005286lndc:CurationFoodsMemberlndc:EatSmartMemberus-gaap:CustomerRelationshipsMember2020-05-310001005286lndc:CurationFoodsMemberlndc:YucatanFoodsLPMemberus-gaap:CustomerRelationshipsMember2020-06-012021-05-300001005286lndc:CurationFoodsMemberlndc:YucatanFoodsLPMemberus-gaap:CustomerRelationshipsMember2021-05-300001005286lndc:CurationFoodsMemberlndc:YucatanFoodsLPMemberus-gaap:CustomerRelationshipsMember2020-05-310001005286us-gaap:CustomerRelationshipsMemberlndc:LifecoreMember2020-06-012021-05-300001005286us-gaap:CustomerRelationshipsMemberlndc:LifecoreMember2021-05-300001005286us-gaap:CustomerRelationshipsMemberlndc:LifecoreMember2020-05-310001005286us-gaap:CustomerRelationshipsMember2021-05-300001005286us-gaap:CustomerRelationshipsMember2020-05-310001005286lndc:CurationFoodsMemberus-gaap:TrademarksAndTradeNamesMemberlndc:EatSmartMember2021-05-300001005286lndc:CurationFoodsMemberus-gaap:TrademarksAndTradeNamesMemberlndc:EatSmartMember2020-06-012021-05-300001005286lndc:CurationFoodsMemberus-gaap:TrademarksAndTradeNamesMemberlndc:EatSmartMember2020-05-310001005286lndc:CurationFoodsMemberus-gaap:TrademarksAndTradeNamesMemberlndc:EatSmartMember2019-05-272020-05-310001005286lndc:CurationFoodsMemberus-gaap:TrademarksAndTradeNamesMemberlndc:OOliveAndVinegarMember2021-05-300001005286lndc:CurationFoodsMemberus-gaap:TrademarksAndTradeNamesMemberlndc:OOliveAndVinegarMember2020-05-310001005286lndc:CurationFoodsMemberus-gaap:TrademarksAndTradeNamesMemberlndc:YucatanFoodsLPMember2021-05-300001005286lndc:CurationFoodsMemberus-gaap:TrademarksAndTradeNamesMemberlndc:YucatanFoodsLPMember2020-05-310001005286us-gaap:TrademarksAndTradeNamesMemberlndc:LifecoreMember2021-05-300001005286us-gaap:TrademarksAndTradeNamesMemberlndc:LifecoreMember2020-05-310001005286us-gaap:TrademarksAndTradeNamesMember2021-05-300001005286us-gaap:TrademarksAndTradeNamesMember2020-06-012021-05-300001005286us-gaap:TrademarksAndTradeNamesMember2020-05-310001005286us-gaap:TrademarksAndTradeNamesMember2019-05-272020-05-310001005286lndc:OOliveAndVinegarMemberus-gaap:CustomerRelationshipsMember2019-05-272020-05-310001005286lndc:OOliveAndVinegarMemberus-gaap:TrademarksAndTradeNamesMember2020-06-012021-05-300001005286lndc:YucatanFoodsLPMemberus-gaap:TrademarksAndTradeNamesMember2020-06-012021-05-300001005286lndc:StockIncentivePlan2019Member2019-10-160001005286us-gaap:EmployeeStockOptionMemberlndc:StockIncentivePlan2019Member2019-10-162019-10-160001005286lndc:StockGrantsAndStockUnitsMemberlndc:StockIncentivePlan2019Member2019-10-162019-10-160001005286lndc:StockIncentivePlan2019Memberus-gaap:StockAppreciationRightsSARSMember2019-10-162019-10-160001005286us-gaap:RestrictedStockUnitsRSUMember2021-05-300001005286lndc:StockIncentivePlan2013Member2013-10-100001005286lndc:StockIncentivePlan2013Member2021-05-300001005286lndc:StockIncentivePlan2009Member2009-10-150001005286lndc:StockIncentivePlan2013Member2017-10-190001005286us-gaap:EmployeeStockOptionMember2020-06-012021-05-300001005286us-gaap:EmployeeStockOptionMember2019-05-272020-05-310001005286us-gaap:EmployeeStockOptionMember2018-05-282019-05-260001005286us-gaap:RestrictedStockMember2018-05-270001005286us-gaap:RestrictedStockMember2018-05-282019-05-260001005286us-gaap:RestrictedStockMember2019-05-260001005286us-gaap:RestrictedStockMember2019-05-272020-05-310001005286us-gaap:RestrictedStockMember2020-05-310001005286us-gaap:RestrictedStockMember2020-06-012021-05-300001005286us-gaap:RestrictedStockMember2021-05-300001005286us-gaap:CostOfSalesMember2020-06-012021-05-300001005286us-gaap:CostOfSalesMember2019-05-272020-05-310001005286us-gaap:CostOfSalesMember2018-05-282019-05-260001005286us-gaap:ResearchAndDevelopmentExpenseMember2020-06-012021-05-300001005286us-gaap:ResearchAndDevelopmentExpenseMember2019-05-272020-05-310001005286us-gaap:ResearchAndDevelopmentExpenseMember2018-05-282019-05-260001005286us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-06-012021-05-300001005286us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-05-272020-05-310001005286us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-05-282019-05-260001005286us-gaap:RestrictedStockUnitsRSUMember2020-06-012021-05-3000010052862010-07-140001005286lndc:CreditAgreementWithJPMorganChaseBMOHarrisBankAndCityNationalBankMemberus-gaap:RevolvingCreditFacilityMember2016-09-230001005286lndc:TermLoanMemberlndc:CreditAgreementWithJPMorganChaseBMOHarrisBankAndCityNationalBankMember2016-09-230001005286lndc:TermLoanMemberlndc:ForthAmendmentCreditAgreementWithJpMorganChaseBmoHarrisBankAndCityNationalBankMember2018-11-300001005286lndc:ForthAmendmentCreditAgreementWithJpMorganChaseBmoHarrisBankAndCityNationalBankMemberus-gaap:RevolvingCreditFacilityMember2018-11-300001005286lndc:TermLoanMemberlndc:SixthAmendmentToTheCreditAgreementWithJPMorganChaseBMOHarrisBankAndCityNationalBankMember2019-10-250001005286lndc:SixthAmendmentToTheCreditAgreementWithJPMorganChaseBMOHarrisBankAndCityNationalBankMemberus-gaap:RevolvingCreditFacilityMember2019-10-250001005286lndc:TermLoanMemberlndc:SixthAmendmentToTheCreditAgreementWithJPMorganChaseBMOHarrisBankAndCityNationalBankMember2019-10-252019-10-250001005286lndc:SeventhAmendmentMember2020-02-230001005286lndc:SixthAmendmentToTheCreditAgreementWithJPMorganChaseBMOHarrisBankAndCityNationalBankMember2020-02-230001005286lndc:SeventhAmendmentMember2021-05-300001005286lndc:SeventhAmendmentMembersrt:MinimumMemberus-gaap:PrimeRateMember2019-05-272020-05-310001005286srt:MaximumMemberlndc:SeventhAmendmentMemberus-gaap:PrimeRateMember2019-05-272020-05-310001005286lndc:SeventhAmendmentMembersrt:MinimumMemberus-gaap:EurodollarMember2019-05-272020-05-310001005286srt:MaximumMemberlndc:SeventhAmendmentMemberus-gaap:EurodollarMember2019-05-272020-05-310001005286lndc:EighthAmendmentMember2020-07-152020-07-150001005286srt:MinimumMemberus-gaap:PrimeRateMemberlndc:EighthAmendmentMember2020-07-152020-07-150001005286srt:MaximumMemberus-gaap:PrimeRateMemberlndc:EighthAmendmentMember2020-07-152020-07-150001005286srt:MinimumMemberus-gaap:EurodollarMemberlndc:EighthAmendmentMember2020-07-152020-07-150001005286srt:MaximumMemberus-gaap:EurodollarMemberlndc:EighthAmendmentMember2020-07-152020-07-150001005286srt:MinimumMemberlndc:EighthAmendmentMember2020-07-152020-07-150001005286srt:MaximumMemberlndc:EighthAmendmentMember2020-07-152020-07-150001005286lndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMemberus-gaap:RevolvingCreditFacilityMember2020-12-310001005286lndc:TermLoanMemberlndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMember2020-12-310001005286lndc:TermLoanMemberlndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMember2020-12-312020-12-310001005286us-gaap:LondonInterbankOfferedRateLIBORMemberlndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2020-12-312020-12-310001005286us-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMemberlndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMemberus-gaap:RevolvingCreditFacilityMember2020-12-312020-12-310001005286lndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMembersrt:MinimumMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2020-12-312020-12-310001005286srt:MaximumMemberlndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2020-12-312020-12-310001005286lndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMemberus-gaap:RevolvingCreditFacilityMember2020-12-312020-12-310001005286lndc:TermLoanMemberlndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMemberus-gaap:BaseRateMember2020-12-312020-12-310001005286lndc:TermLoanMemberus-gaap:LondonInterbankOfferedRateLIBORMemberlndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMember2020-12-312020-12-310001005286lndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMember2020-12-310001005286lndc:CreditAgreementWithBMOHarrisBankGoldmanSachsSpecialtyLendingGroupLPAndGuggenheimCreditServicesLLCMemberus-gaap:RevolvingCreditFacilityMember2020-06-012021-05-300001005286us-gaap:EurodollarMemberlndc:SixthAmendmentToTheCreditAgreementWithJPMorganChaseBMOHarrisBankAndCityNationalBankMemberus-gaap:RevolvingCreditFacilityMember2021-05-300001005286lndc:TermLoanMemberlndc:CreditAgreementWithJPMorganChaseBMOHarrisBankAndCityNationalBankMember2021-05-300001005286lndc:TermLoanMember2021-05-300001005286lndc:TermLoanMember2020-05-310001005286lndc:BMOMemberus-gaap:InterestRateSwapMember2016-11-010001005286us-gaap:LondonInterbankOfferedRateLIBORMemberlndc:BMOMemberus-gaap:InterestRateSwapMember2016-11-010001005286lndc:BMOMemberus-gaap:InterestRateSwapMember2018-06-250001005286us-gaap:LondonInterbankOfferedRateLIBORMemberlndc:BMOMemberus-gaap:InterestRateSwapMember2018-06-250001005286lndc:BMOMemberus-gaap:InterestRateSwapMember2019-12-020001005286us-gaap:LondonInterbankOfferedRateLIBORMemberlndc:BMOMemberus-gaap:InterestRateSwapMember2019-12-020001005286us-gaap:DomesticCountryMember2021-05-300001005286us-gaap:ForeignCountryMember2021-05-300001005286stpr:CA2021-05-300001005286stpr:IN2021-05-300001005286lndc:OtherStatesTaxBoardMember2021-05-300001005286stpr:MN2021-05-300001005286us-gaap:DomesticCountryMember2020-06-012021-05-300001005286stpr:MN2020-06-012021-05-300001005286us-gaap:StateAndLocalJurisdictionMember2021-05-30utr:sqft00010052862015-09-03lndc:renewalOption00010052862015-09-032015-09-0300010052862021-05-012021-05-31lndc:attemptsToUnionize0001005286lndc:DiscriminationAndWrongfulTerminationAndWageAndHourClaimsMemberlndc:PacificHarvestMember2021-05-30lndc:employee0001005286lndc:DiscriminationAndWrongfulTerminationAndWageAndHourClaimsMemberlndc:PacificHarvestMember2020-06-012021-05-30lndc:plaintifflndc:installment00010052862017-05-280001005286lndc:DiscriminationAndWrongfulTerminationAndWageAndHourClaimsMemberlndc:PacificHarvestMember2017-05-280001005286lndc:DiscriminationAndWrongfulTerminationAndWageAndHourClaimsMemberlndc:PacificHarvestMember2020-05-3100010052862020-09-022020-09-0200010052862020-11-0300010052862020-11-302021-02-280001005286lndc:DiscriminationAndWrongfulTerminationAndWageAndHourClaimsMember2017-05-292018-05-270001005286lndc:DiscriminationAndWrongfulTerminationAndWageAndHourClaimsMemberlndc:PacificHarvestMember2017-05-292018-05-27lndc:segmentlndc:brand0001005286country:US2021-05-300001005286country:US2020-05-310001005286country:MX2021-05-300001005286country:MX2020-05-310001005286country:CA2020-06-012021-05-300001005286country:CA2019-05-272020-05-310001005286country:CA2018-05-282019-05-260001005286country:BE2020-06-012021-05-300001005286country:BE2019-05-272020-05-310001005286country:BE2018-05-282019-05-260001005286country:CH2020-06-012021-05-300001005286country:CH2019-05-272020-05-310001005286country:CH2018-05-282019-05-260001005286country:CZ2020-06-012021-05-300001005286country:CZ2019-05-272020-05-310001005286country:CZ2018-05-282019-05-260001005286country:IE2020-06-012021-05-300001005286country:IE2019-05-272020-05-310001005286country:IE2018-05-282019-05-260001005286lndc:AllOtherCountriesMember2020-06-012021-05-300001005286lndc:AllOtherCountriesMember2019-05-272020-05-310001005286lndc:AllOtherCountriesMember2018-05-282019-05-260001005286us-gaap:AllOtherSegmentsMember2020-06-012021-05-300001005286lndc:CurationFoodsMember2021-05-300001005286lndc:LifecoreMember2021-05-300001005286us-gaap:AllOtherSegmentsMember2021-05-300001005286us-gaap:AllOtherSegmentsMember2019-05-272020-05-310001005286lndc:CurationFoodsMember2020-05-310001005286lndc:LifecoreMember2020-05-310001005286us-gaap:AllOtherSegmentsMember2020-05-310001005286us-gaap:AllOtherSegmentsMember2018-05-282019-05-260001005286lndc:CurationFoodsMember2019-05-260001005286lndc:LifecoreMember2019-05-260001005286us-gaap:AllOtherSegmentsMember2019-05-2600010052862020-06-012020-08-3000010052862020-08-312020-11-2900010052862021-03-012021-05-3000010052862019-05-272019-08-2500010052862019-08-262019-11-2400010052862019-11-252020-02-2300010052862020-02-242020-05-310001005286lndc:NowPlantingAndFoodExportMemberus-gaap:SegmentDiscontinuedOperationsMember2020-06-012021-05-300001005286lndc:NowPlantingAndFoodExportMemberus-gaap:SegmentDiscontinuedOperationsMember2019-05-272020-05-310001005286lndc:NowPlantingAndFoodExportMemberus-gaap:SegmentDiscontinuedOperationsMember2018-05-282019-05-260001005286lndc:NowPlantingMemberus-gaap:SegmentDiscontinuedOperationsMember2020-06-012021-05-300001005286lndc:NowPlantingMemberus-gaap:SegmentDiscontinuedOperationsMember2019-05-272020-05-310001005286lndc:NowPlantingMemberus-gaap:SegmentDiscontinuedOperationsMember2018-05-282019-05-260001005286lndc:AssetWriteOffCostsMemberlndc:CurationFoodsMember2020-06-012021-05-300001005286lndc:AssetWriteOffCostsMemberlndc:LifecoreMember2020-06-012021-05-300001005286lndc:AssetWriteOffCostsMemberus-gaap:AllOtherSegmentsMember2020-06-012021-05-300001005286lndc:AssetWriteOffCostsMember2020-06-012021-05-300001005286lndc:CurationFoodsMemberus-gaap:EmployeeSeveranceMember2020-06-012021-05-300001005286us-gaap:EmployeeSeveranceMemberlndc:LifecoreMember2020-06-012021-05-300001005286us-gaap:AllOtherSegmentsMemberus-gaap:EmployeeSeveranceMember2020-06-012021-05-300001005286us-gaap:EmployeeSeveranceMember2020-06-012021-05-300001005286lndc:LeaseCostsMemberlndc:CurationFoodsMember2020-06-012021-05-300001005286lndc:LeaseCostsMemberlndc:LifecoreMember2020-06-012021-05-300001005286lndc:LeaseCostsMemberus-gaap:AllOtherSegmentsMember2020-06-012021-05-300001005286lndc:LeaseCostsMember2020-06-012021-05-300001005286lndc:CurationFoodsMemberus-gaap:OtherRestructuringMember2020-06-012021-05-300001005286us-gaap:OtherRestructuringMemberlndc:LifecoreMember2020-06-012021-05-300001005286us-gaap:AllOtherSegmentsMemberus-gaap:OtherRestructuringMember2020-06-012021-05-300001005286us-gaap:OtherRestructuringMember2020-06-012021-05-300001005286us-gaap:EquipmentMember2020-11-302021-02-280001005286lndc:AssetWriteOffCostsMemberlndc:CurationFoodsMember2019-05-272021-05-300001005286lndc:AssetWriteOffCostsMemberlndc:LifecoreMember2019-05-272021-05-300001005286lndc:AssetWriteOffCostsMemberus-gaap:AllOtherSegmentsMember2019-05-272021-05-300001005286lndc:AssetWriteOffCostsMember2019-05-272021-05-300001005286lndc:CurationFoodsMemberus-gaap:EmployeeSeveranceMember2019-05-272021-05-300001005286us-gaap:EmployeeSeveranceMemberlndc:LifecoreMember2019-05-272021-05-300001005286us-gaap:AllOtherSegmentsMemberus-gaap:EmployeeSeveranceMember2019-05-272021-05-300001005286us-gaap:EmployeeSeveranceMember2019-05-272021-05-300001005286lndc:LeaseCostsMemberlndc:CurationFoodsMember2019-05-272021-05-300001005286lndc:LeaseCostsMemberlndc:LifecoreMember2019-05-272021-05-300001005286lndc:LeaseCostsMemberus-gaap:AllOtherSegmentsMember2019-05-272021-05-300001005286lndc:LeaseCostsMember2019-05-272021-05-300001005286lndc:CurationFoodsMemberus-gaap:OtherRestructuringMember2019-05-272021-05-300001005286us-gaap:OtherRestructuringMemberlndc:LifecoreMember2019-05-272021-05-300001005286us-gaap:AllOtherSegmentsMemberus-gaap:OtherRestructuringMember2019-05-272021-05-300001005286us-gaap:OtherRestructuringMember2019-05-272021-05-300001005286lndc:CurationFoodsMember2019-05-272021-05-300001005286lndc:LifecoreMember2019-05-272021-05-300001005286us-gaap:AllOtherSegmentsMember2019-05-272021-05-3000010052862019-05-272021-05-30
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended May 30, 2021, or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition period from _________ to _________.
Commission file number: 000-27446
LANDEC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware94-3025618
(State or other jurisdiction of incorporation or organization)(IRS Employer Identification Number)

2811 Airpark Drive
Santa Maria,California93455
(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code:
(650) 306-1650

Securities registered pursuant to Section 12(b) of the Act:

 Title of each class 
Trading Symbol
 Name of each exchange on which registered
Common Stock, par value $0.001 per share
LNDC
The NASDAQ Global Select Stock Market

Securities registered pursuant to Section 12(g) of the Act:
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated FilerAccelerated Filer
Non Accelerated FilerSmaller Reporting Company
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No ☒
The aggregate market value of voting stock held by non-affiliates of the Registrant was approximately $210,110,000 as of November 29, 2020, the last business day of the registrant’s most recently completed second fiscal quarter, based upon the closing sales price on The NASDAQ Global Select Market reported for such date. Shares of Common Stock held by each officer and director and by each person who owns 10% or more of the outstanding Common Stock have been excluded from such calculation in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of July 26, 2021, there were 29,456,705 shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement relating to its 2021 Annual Meeting of Stockholders (the “Proxy Statement”) to be filed with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, are incorporated herein by reference where indicated. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement is not deemed to be filed as part hereof.














1

Table of Contents
LANDEC CORPORATION
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
Item No.
DescriptionPage
   
   
   
 

i

Table of Contents
Cautionary Note About Forward-Looking Statements
This Annual Report on Form 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Potential risks and uncertainties include, without limitation, the timing and expenses associated with operations, the ability to achieve acceptance of our new products in the market place, weather conditions that can affect the supply and price of produce, government regulations affecting our business, uncertainties related to COVID-19 and the impact of our responses to it, the timing of regulatory approvals, the ability to successfully integrate Yucatan Foods into the Curation Foods business, the mix between domestic and international sales, and those other risks mentioned in Item 1A. “Risk Factors” of this report.
We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Accordingly, our actual results could differ materially from those projected in the forward-looking statements for many reasons, including the risk factors listed in Item 1A. “Risk Factors” of this report.
All forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements as well as others made in this report and hereafter in our other SEC filings and public communications.
You should evaluate all forward-looking statements made by us in the context of all risks and uncertainties described with respect to our business. We caution you that the risks and uncertainties identified by us may not be all of the factors that are important to you. Furthermore, the forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

PART I

Item 1.    Business
Corporate Overview
Landec Corporation and its subsidiaries (“Landec,” the “Company”, "we" or "us") design, develop, manufacture, and sell differentiated products for food and biomaterials markets, and license technology applications to partners.
Landec’s natural food company, Curation Foods, Inc. (“Curation Foods”) is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology.
Landec’s biomedical company, Lifecore Biomedical, Inc. (“Lifecore”), is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of sterile, injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 36 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.
Landec was incorporated in California on October 31, 1986 and reincorporated as a Delaware corporation on November 6, 2008. Landec’s common stock is listed on The NASDAQ Global Select Market under the symbol “LNDC”. The Company’s principal executive offices are located at 2811 Airpark Drive Santa Maria, California 93455, and the telephone number is (650) 306-1650.

1

Table of Contents
Reportable Segments
Landec has three reportable business segments – Curation Foods, Lifecore and Other, which are described below. During the fourth quarter of fiscal years 2019 the Company discontinued its Now Planting® business. The operating results for the Now Planting business are presented as discontinued operations in the Company’s accompanying Consolidated Financial Statements and the financial results for fiscal years 2021, 2020 and 2019.
Curation Foods
Curation Foods Overview
Based in Santa Maria, California, Curation Foods’ primary business is the processing, marketing and selling of fresh packaged plant based salads and vegetables. Curation Foods serves as the corporate umbrella for its patented BreatheWay® packaging technology and for its portfolio of four natural food brands, including the Company’s legacy and flagship brand Eat Smart® as well as its three more recently acquired natural food brands, O Olive Oil & Vinegar® (“O”) products, and Yucatan® and Cabo Fresh® authentic guacamole and avocado products. The major distinguishing characteristics of Curation Foods that provide competitive advantage are insight driven product innovation, diversified fresh food supply chain, refrigerated supply chain and customer reach. We believe that Curation Foods is well positioned as a single source of a broad range of products. Curation Foods also has six processing facilities. In addition to processing, the company has two distribution centers and a nationwide network of third party providers for nationwide delivery of all of its packaged salads, vegetable products, avocado products and specialty oil and vinegar products. Our products are currently available in over 74% of retail and club stores across North America.
During fiscal 2019, the Company redefined the strategy for its Curation Foods segment in order to improve the Company’s overall profitability by launching Project SWIFT, a value creation program designed to transform the Curation Foods business by simplifying the business, realigning its resources and seeking to improve the Company’s balance sheet through three strategic priorities - optimizing its operations networks, maximizing strategic assets and redesigning the organization to be more competitive.
Curation Foods Brands
Eat Smart: The Company sells specialty fresh packaged Eat Smart branded and private label salads, fresh-cut vegetables and whole produce to retailers, club stores, and food service operators, primarily in the United States and Canada. Within the Eat Smart brand, produce is processed by trimming, washing, sorting, blending, and packaging into bags and trays.
O Olive Oil & Vinegar: The Company acquired O on March 1, 2017. O, founded in 1995, is based in Petaluma, California, and is the premier producer of California specialty olive oils and wine vinegars. Its products are sold in natural food, conventional grocery and mass retail stores, primarily in the United States and Canada.
Yucatan & Cabo Fresh Avocado Products: The Company acquired Yucatan Foods on December 1, 2018. Yucatan Foods was founded in 1991. As part of the acquisition of Yucatan Foods, Curation Foods acquired the newly built production facility in Guanajuato, Mexico. The Yucatan Foods business added a double-digit growth platform, a lower-cost infrastructure in Mexico, and higher margin product offerings that generally exhibit less sourcing volatility. The Company manufactures and sells Yucatan and Cabo Fresh guacamole and avocado food products primarily to the U.S. grocery channel, but also to the U.S. mass retail, Canadian grocery retail and foodservice channels.
BreatheWay Packaging Technology: The Company’s BreatheWay membrane technology establishes a beneficial packaging atmosphere adapting to changing fresh product respiration and temperature in order to extend freshness naturally. The BreatheWay supply chain packaging technology extends shelf-life and reduces shrink (waste) for retailers and helps to ensure that consumers receive fresh products. The Company generates revenue from the sale to and/or use of its BreatheWay patented packaging technology and integrated packaging solutions.
Windset: Until June 1, 2021, the Company held a 26.9% investment ownership in Windset Holding 2010 Ltd. (“Windset”), a leading edge grower of hydroponically-grown produce. Windset owns and operates greenhouses in British Columbia, Canada and California. In addition to growing produce in its own greenhouses, Windset has numerous marketing arrangements with other greenhouse growers and utilizes buy/sell arrangements to meet fluctuation in demand from their customers. The Curation Foods segment operating results include the dividends and Landec’s share of the change in fair market value of its investment in Windset.

2

Table of Contents
On June 1, 2021, the Company and Curation Foods entered into and closed a Share Purchase Agreement (the “Purchase Agreement”) with Newell Capital Corporation and Newell Brothers Investment 2 Corp., as Purchasers (the “Purchasers”) and Windset, pursuant to which Curation Foods sold all of its equity interests of Windset to the Purchasers in exchange for an aggregate purchase price of $45.1 million. Pursuant to the terms of the Purchase Agreement, Curation Foods also retained certain rights to additional purchase price consideration in the event of certain transactions or equity issuances involving Windset until September 2022. The Purchase Agreement included various representations, warranties and covenants of the parties generally customary for a transaction of this nature.
Lifecore Biomedical

Lifecore, located in Chaska, Minnesota, is a fully integrated CDMO that offers highly differentiated capabilities in the development, fill and finish of sterile, injectable pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (“HA”) in bulk form as well as formulated and filled syringes and vials for injectable products used in treating a broad spectrum of medical conditions and procedures. Lifecore uses its fermentation process and aseptic formulation and filling expertise to be a leader in the development of HA-based products for multiple applications and to take advantage of non-HA device and drug opportunities which leverage its expertise in manufacturing and aseptic syringe filling capabilities.

Lifecore CDMO provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated and filled products. These services include activities such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation and production of materials for clinical studies.

Built over many years of experience, Lifecore separates itself from its competition based on its five areas of expertise, including but not limited to Lifecore’s ability to:

Establish strategic relationships with market leaders:
Lifecore continues to develop applications for products with partners who have strong marketing, sales, and distribution capabilities to end-user markets. Through its strong reputation and history of providing pharmaceutical grade HA and products, Lifecore has established long-term relationships with global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories, and leverages those partnerships to attract new relationships in other medical markets.
Expand medical applications for HA:
Due to the growing knowledge of the unique characteristics of HA and Lifecore’s unique strength and history as a trusted manufacturer of pharmaceutical injectable grade HA products, Lifecore continues to identify and pursue opportunities for the use of HA in other medical applications, such as wound care, aesthetic surgery, drug delivery, next generation orthopedics and device coatings, and through sales to academic and corporate research customers. Further applications may involve expanding process development activity and/or additional licensing of technology.
Utilize manufacturing infrastructure to meet customer demand:
Lifecore has made strategic capital investments in its CDMO business focusing on extending its aseptic filling capacity and capabilities to meet increasing partner demand and to attract new contract filling opportunities outside of HA markets. Lifecore is using its manufacturing capabilities to provide contract manufacturing and development services to its partners in the area of sterile pre-filled syringes and vials, as well as fermentation and purification requirements.
Maintain flexibility in product development and supply relationships:
Lifecore’s vertically integrated development and manufacturing capabilities allow it to establish a variety of contractual relationships with global corporate partners. Lifecore’s role in these relationships extends from supplying HA raw materials to providing technology transfer and development services to manufacturing aseptically filled, finished sterile products, and assuming full supply chain responsibilities.

Deliver consistent quality:
Lifecore has built a world class quality and regulatory system that is demonstrated in their results, processes and customer relationships. With over 35 years of a superior track record with global regulatory bodies (FDA, EMA, ANVISA, etc.), Lifecore is the partner of choice for companies looking for proven experience in delivering QbD, cGMP compliance, and manufacturing excellence with pharmaceutical elegance and quality. Lifecore’s world class quality and regulatory system and excellent track record with the global regulatory bodies ensure partners that they will safely bring innovative therapies to market.
3

Table of Contents
Other
Included in the Other segment is Corporate, which includes corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income and income tax expenses.
COVID-19 Pandemic
There are many uncertainties regarding the current novel coronavirus (“COVID-19”) pandemic, including the scope of scientific and health issues, the anticipated duration of the pandemic, and the extent of local and worldwide social, political, and economic disruption it may cause. The COVID-19 pandemic has had and we believe will continue to have significant adverse impacts on many aspects of the Company’s operations, directly and indirectly, including with respect to sales, customer behaviors, business and manufacturing operations, inventory, the Company’s employees, and the market generally, and the scope and nature of these impacts continue to evolve each day. The Company expects to continue to assess the evolving impact of the COVID-19 pandemic, and intends to continue to make adjustments to its responses accordingly.

Sales and Marketing
Curation Foods is supported by dedicated sales and marketing teams located throughout the U.S. and Canada.
Lifecore relies on name recognition and referrals regarding its biomedical-based CDMO and manufacturing experience and expertise to attract new customers and offers its services with minimal marketing and sales infrastructure.
Manufacturing and Processing
Seasonality
Curation Foods can be affected by seasonal weather factors, which can result in higher costs of sourcing and processing its produce products due to a shortage of essential produce items. Lifecore is not significantly affected by seasonality.
Curation Foods
Eat Smart Fresh Packaged Salads and Vegetables

Fresh packaged salads, vegetable products and fresh-cut packaged green beans are processed in the Company’s facilities located in Guadalupe, California and Bowling Green, Ohio. Cooling of produce is done by third parties as well as our own cooling systems. As part of Landec’s Project SWIFT, during the second quarter of fiscal year 2021, the Company sold the Hanover building and assets related thereto for net proceeds of $8.0 million.
O Olive Oil & Vinegar
O uses third parties to crush, process, and bottle its olive oil products, primarily within California. The fermentation, production, and processing of vinegar is performed at the Company’s facility in Petaluma, California, using ingredients sourced from various third parties primarily within California. O uses third parties in California to bottle its vinegar products.
Yucatan and Cabo Fresh
Guacamole for the Yucatan and Cabo Fresh brands is primarily produced and packed at the Company’s facility in Guanajuato, Mexico, using ingredients sourced from various third parties within the United States and Mexico.
BreatheWay
BreatheWay packaging systems use polymer manufacturing, membrane manufacturing, and label package conversion. Contract manufacturers currently make virtually all of the polymers for the BreatheWay packaging system and breathable membranes. The Company performs the label package conversion in its various processing facilities.

4

Table of Contents
Lifecore Biomedical
The commercial production of HA requires fermentation, separation, and purification and aseptic processing capabilities. HA can primarily be produced in two ways, either through bacterial fermentation or through extraction from rooster combs. Lifecore produces HA only from bacterial fermentation, using an efficient microbial fermentation process and an effective purification operation.
Lifecore’s facilities in Chaska, Minnesota are used for the HA and non-HA manufacturing process, formulation, aseptic syringe and vial filling, analytical services, secondary packaging, warehousing raw materials and finished goods, and distribution. Lifecore provides versatility in the manufacturing of various types of finished products and supplies several different forms of HA and non-HA products in a variety of molecular weight fractions as powders, solutions and gels, and in a variety of bulk and single-use finished packages. As of the date of this report, the Company believes that its current manufacturing capacity plan will be sufficient to allow it to meet the needs of its current customers for the foreseeable future.
Competition
The Company operates in highly competitive and rapidly evolving fields, and new developments are expected to continue at a rapid pace. Competition from large food-products, industrial, medical and pharmaceutical companies is expected to be intense. In addition, the nature of our collaborative arrangements may result in our business partners and licensees becoming our competitors. Many of our competitors have substantially greater financial and technical resources and production and marketing capabilities than we do, and may have substantially greater experience in conducting clinical and field trials, obtaining regulatory approvals and manufacturing and marketing commercial products.
The food industry is highly competitive, and further consolidation with our customers would likely increase competition. The Company’s principal competitors, Taylor Farms, Fresh Express and Dole, have substantial financial, marketing, and other resources. Increased competition can reduce our sales due to loss of market share or the need to reduce prices to respond to competitive and customer pressures. Competitive pressures also may restrict our ability to increase prices, including in response to commodity and other cost increases. We sell branded, private brand, and customized food products, as well as commercially branded foods. Our branded products have an advantage over private brand products primarily due to advertising and name recognition, although private brand products typically sell at a discount to those of branded competitors. In addition, when branded competitors focus on price and promotion, the environment for private brand producers becomes more challenging because the price difference between private brand products and branded products may become less significant. In most product categories, we compete not only with other widely advertised branded products, but also with other private label and store brand products that are generally sold at lower prices. A strong competitive response from one or more of our competitors to our marketplace efforts, or a consumer shift towards more generic, lower-priced, or other value offerings, could result in us reducing pricing, increasing marketing or other expenditures, or losing market share. Our margins and profits could decrease if a reduction in prices or increased costs are not counterbalanced with increased sales volume.
In addition, substantial growth in e-commerce has encouraged the entry of new competitors and business models, intensifying competition by simplifying distribution and lowering barriers to entry. The expanding presence of e-commerce retailers has impacted, and may continue to impact, consumer preferences and market dynamics, which in turn may negatively affect our sales or profits.
Patents and Proprietary Rights
The Company’s success depends in large part on its ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of third parties. The Company has 19 active U.S. patents as of May 30, 2021 with expiration dates ranging from 2021 to 2035.

Government Regulation
Curation Foods
The Company’s food products and operations are also subject to regulation by various foreign, federal, state, and local agencies, with respect to production processes, product attributes, packaging, labeling, advertising, import, export, storage, transportation and distribution.
In the U.S., food products are primarily regulated by the Food and Drug Administration (“FDA”), which has the authority to inspect the Company’s food facilities, and regulates, among other things, food manufacturing, food packing and holding, food additives, food safety, the growing and harvesting of produce intended for human consumption, food transportation,
5

Table of Contents
food labeling, food packaging, and food supplier controls including foreign supplier verification. In addition, advertising of our products is subject to regulation by the Federal Trade Commission (“FTC”), and operations are subject to certain health and safety regulations, such as those issued under the Occupational Safety and Health Act (“OSHA”). All of our U.S. facilities and food products must be in compliance with the Federal Food, Drug, and Cosmetic Act (“FDC Act”) as amended by, among other things, the FDA Food Safety Modernization Act (“FSMA”). In addition, our operations in Mexico are subject to Mexican regulations through the SAGARPA, and our food products sold into Canada must be in compliance with applicable Canadian food safety and labeling regulations.
Lifecore
The FDA regulates and/or approves the clinical trials, manufacturing, labeling, distribution, import, export, sale and promotion of medical devices and drug products in or from the United States. Some of the Company’s and its customers’ products are subject to extensive and rigorous regulation by the FDA, which regulates some of the products as medical devices or drug products, that in some cases require FDA approval or clearance, prior to U.S. distribution of Pre-Market Approval (“PMA”), or New Drug Applications (“NDA”), or Pre-Market Notifications, or other submissions and by foreign countries, which regulate some of the products as medical devices or drug products.
Other regulatory requirements are placed on the design, manufacture, processing, packaging, labeling, distribution, record-keeping and reporting of a medical device or drug products and on the quality control procedures. For example, medical device and drug manufacturing facilities are subject to periodic inspections by the FDA to assure compliance with device and/or drug requirements, as applicable. The FDA also conducts pre-approval inspections for PMA and NDA product introduction. Lifecore’s facility is subject to inspections as both a device and a drug manufacturing operation. For PMA devices and NDA drug products, the company that owns the product submission is required to submit an annual report and also to obtain approval, as applicable, for modifications to the device, drug product, or its labeling. Similarly, companies that own FDA Pre-Market Notifications for marketed products must obtain additional FDA clearance for certain modifications to their devices or labeling. Other applicable FDA requirements include but are not limited to reporting requirements such as the medical device reporting regulation, which requires certain companies to provide information to the FDA regarding deaths or serious injuries alleged to have been associated with the use of its devices, as well as product malfunctions that would likely cause or contribute to death or serious injury if the malfunction were to recur. FDA also maintains adverse event reporting requirements for drug products, among other post-market regulatory requirements.

Human Capital

Our mission

The strength of our team and our workplace culture is essential to our ability to achieve our broader mission. Attracting, developing and retaining exceptional employees is vitally important to us, and we invest in creating a differentiated culture for our team that enables continuous innovation at scale. We want to be a force for good, a team that is helping to improve the quality of life for our customers and employees. As of May 30, 2021, Landec had 905 full-time employees, of whom 675 were dedicated to research, development, manufacturing, quality control and regulatory affairs, and 230 were dedicated to sales, marketing and administrative activities. Landec intends to recruit additional personnel in connection with the development, manufacturing and marketing of its products.

Our employee engagement and culture

Our hiring process has been designed to provide an equitable candidate experience, facilitate the inclusion of new perspectives, foster innovation and creativity and leverage technology and data analytics to address gaps in representation.

We developed a COVID-19 Taskforce to assure employee health and safety throughout the workplace and encourage employees to carry this information into their communities. We also partner with local health departments in our various locations to supply our employees with COVID-19 communications to keep them informed in the ever-changing environment.

We provide training to all employees in the areas of Food Safety, Human Safety and Human Resources. Individual training plans for continued growth are developed between employees and supervisors or managers. Frontline supervision workers at factory locations are provided continuous improvement tools for training in line with our "ZEST" efforts as well as employee interface training covering topics such as how to provide feedback or how to have difficult conversations regarding performance. ZEST is our manufacturing operational system that will empower our people to work in a different way, changing their mindset and behaviors leading to an acceleration of our performance across our operations.

6

Table of Contents
Zero Mindset - Zero breakdown, zero defects, zero recalls, zero accidents, zero pollution.
Empowerment - Empower employees to impact change. I operate. I maintain. I own the outcomes.
Standardization - Implementing the same practice across the network for efficiency.
Training - The cornerstone of success and employee engagement.

We empower our employees to own their career path and seek out training programs to take them to the next level. We are currently in the process of developing a platform for growth opportunities and ways to understand and communicate career pathways. We have also invested in our training and development programs and infrastructure for our employees.

Available Information
Landec’s website is www.landec.com. Landec makes available free of charge copies of its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after filing such material electronically with, or otherwise furnishing it to, the U.S. Securities and Exchange Commission (“SEC”). In addition, these materials may be obtained at the website maintained by the SEC at www.sec.gov. The reference to the Company’s website address does not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document.

Item 1A.    Risk Factors
Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business, prospects, financial condition and results of operations, any of which could subsequently have an adverse effect on the trading price of our common stock, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors in its entirety, in addition to other information contained in or incorporated by reference into this Annual Report on Form 10-K and our other public filings with the SEC. Additional risks not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and results of operations in future periods.

Risks Related to Our Business and Operations
Our shareholder value creation program, Project SWIFT, may not have the anticipated results, exposes us to additional restructuring costs and operational risks, and may be negatively perceived in the markets.
We have previously announced the development of a shareholder value creation program, Project SWIFT, designed to strategically realign our Curation Foods business to focus the business on its strategic assets and redesign the organization to be the appropriate size to compete and thrive. This program includes reviewing strategic options for our legacy vegetable bag and tray business, the closure of certain leased offices in Santa Clara, California and Los Angeles, California, the divestiture of our yet-to-be-operational salad dressing plant in Ontario, California, divestiture of our underutilized Hanover manufacturing facility, strategic review of our logistics operations and certain other actions taken to redesign the Curation Foods organization. We may not be able to implement all of the actions that we intend to take in this program and we may not be able to realize the expected benefits from such realignment and restructuring plans or other similar restructurings on the anticipated timing, or at all. In addition, we may incur additional restructuring costs in implementing such realignment and restructuring plans or other similar future plans in excess of our expectations. The implementation of our restructuring efforts, including the potential reduction of our facilities and workforce, may not improve our operational and cost structure or result in greater efficiency of our organization; and we may not be able to support sustainable revenue growth and profitability following such restructurings. Any reduction in workforce or divestitures of facilities or other assets may also expose us to additional risks, including potential litigation (including labor and employment disputes), unforeseen costs or adverse impacts to the operations of our retained businesses. In addition, our strategic realignment efforts may not be viewed positively by shareholders and analysts, which may cause our stock price to decline or become volatile.
The COVID-19 Pandemic, or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide may adversely affect our business.
In December 2019, a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. This virus continues to spread globally and, as of May 31, 2020, has spread to approximately 160 countries, including the United States. To date, the COVID-19 pandemic and preventative measures taken to contain or mitigate the outbreak have caused, and are continuing to cause, business slowdowns or shutdowns in affected areas and significant disruption to our businesses and to the financial markets both globally and in the United States. The COVID-19 pandemic has had and we believe will continue to have significant adverse
7

Table of Contents
impacts on many aspects of the Company’s operations, directly and indirectly, including with respect to sales, customer behaviors, business and manufacturing operations, inventory, the Company’s employees, and the market generally, and the scope and nature of these impacts continue to evolve each day. In particular, the COVID-19 pandemic has resulted in and may continue to result in, regional quarantines, labor shortages or stoppages, adverse changes in consumer purchasing patterns, reductions in customer demand for our products, increased safety and compliance costs, disruptions to our supply chains, suppliers and service providers to deliver materials and services on a timely basis, and overall economic instability, which have significantly adversely affected and could further adversely affect our business, financial condition and results of operations. In addition, in response to the COVID-19 pandemic, our suppliers, growers, and corporate partners have reduced staffing and have reduced, delayed and postponed certain projects, initiatives or other arrangements in response to the spread of the COVID-19 pandemic, which may continue or worsen as the pandemic continues. These actions have resulted in and may result in further business and manufacturing disruption, inventory shortages, delivery delays, additional costs, and reduced sales and operations for us, any of which have and could further significantly affect our business, financial condition and results of operations. With respect to our Curation Foods business specifically, the responses to the COVID-19 pandemic have also adversely impacted and may further impact consumer spending and our customer’s preferences, which have had and may continue to have an adverse impact on our sales in that segment. With respect to our Lifecore business, the COVID-19 pandemic has resulted and may continue to result in fewer elective medical procedures, which, in turn, has and may continue to adversely impact our business and sales. The extent to which the COVID-19 pandemic has impacted our business is difficult to ascertain, and future potential impacts to our business will depend on how the COVID-19 pandemic continues to evolve, which is highly uncertain and cannot be predicted. Such future developments may include, among others, new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact. The COVID-19 pandemic has adversely affected the economies and financial markets worldwide, resulting in an economic downturn that could affect demand for our products, our ability to obtain financing on favorable terms, our ability to comply with our obligations (including leases and debt covenants) and otherwise adversely impact our business, financial condition and results of operations.
The situation surrounding the COVID-19 pandemic remains fluid, and given its inherent uncertainty, we expect that it will continue to have significant adverse impacts on our business in the future. The duration and extent of the impact from the COVID-19 pandemic, or any other future pandemic, epidemic or outbreak, depends on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus and its variants, the extent and effectiveness of containment actions and the impact of these and other factors on our employees, customers, suppliers, distributors and manufacturers. Should these conditions persist for a prolonged period, the COVID-19 pandemic, including any of the above factors and others that are currently unknown, could continue to have a significant adverse effect on our business, financial condition and results of operations. The impact of the COVID-19 pandemic may also exacerbate other risks discussed elsewhere in this Report, any of which could have a material effect on us.
Our credit facilities provides our lenders with a lien against substantially all of our assets, and contains financial covenants that may limit our operational flexibility and cash flow available to invest in the ongoing needs of our business or otherwise adversely affect our results of operations.
We are party to two credit agreements, which contain a number of covenants that limit our ability and our subsidiaries’ ability to, among other things, incur additional indebtedness, pay dividends, create liens, engage in transactions with affiliates, merge or consolidate with other companies, or sell substantially all of our assets. We are also required to maintain certain financial covenants, including a maximum total leverage ratio and a minimum fixed charge coverage ratio. The terms of our credit facilities may restrict our current and future operations and could adversely affect our ability to finance our future operations or capital needs or to execute preferred business strategies. In addition, complying with these covenants may make it more difficult for us to successfully execute our business strategy and compete against companies who are not subject to such restrictions.
A failure by us to comply with the covenants specified in our credit agreements, as amended, could result in an event of default under the agreements, which would give the lenders the right to terminate their commitments to provide additional loans under our credit facilities and to declare all borrowings outstanding, together with accrued and unpaid interest, to be immediately due and payable. In addition, the lenders would have the right to proceed against the collateral we granted to them, which consists of substantially all of our assets. We cannot guarantee that we will be able to remain in compliance with all applicable covenants under the credit agreements in the future, that our lenders will elect to provide waivers or enter into amendments in the future, or, if the lenders do provide waivers, that those waivers will not be conditioned upon additional costs or restrictions that could materially or adversely impact our business, cash flows, results of operations, and financial condition. In addition, if the debt under our credit facilities were to be accelerated, we may not have sufficient cash or be able to borrow sufficient funds to refinance the debt or sell sufficient assets to repay the debt, which could immediately, materially and adversely affect our business, cash flows, results of operations, and financial condition, and there would be no guarantee that we would be able to find alternative financing. Even if we were able to obtain alternative financing, it may not be available on commercially reasonable terms or on terms that are acceptable to us.
8

Table of Contents
Our ability to make payments on our debt, fund our other liquidity needs, and make planned capital expenditures will depend on our ability to generate cash in the future. Our historical financial results have been, and we anticipate that our future financial results will be, subject to fluctuations. Our ability to generate cash, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory, and other factors that are beyond our control. We cannot guarantee that our business will generate sufficient cash flow from our operations or that future borrowings will be available to us in an amount sufficient to enable us to make payments of our debt, fund other liquidity needs, and make planned capital expenditures.

Adverse weather conditions and other acts of god may cause substantial decreases in our sales and/or increases in our costs
Our packaged fresh salads and vegetables business is subject to weather conditions that affect commodity prices, crop quality and yields, and crop varieties to be planted. Crop diseases and severe conditions, particularly weather conditions such as unexpected or excessive rain or other precipitation, unseasonable temperature fluctuations, floods, heat waves, droughts, frosts, windstorms, earthquakes and hurricanes, may adversely affect the supply of vegetables and fruits used in our business, which could reduce the sales volumes and/or increase the unit production costs. The Company regularly experiences significant product sourcing issues as a result of severe adverse weather conditions that materially adversely affected the Company’s financial results. Because a significant portion of the costs are fixed and contracted in advance of each operating year, volume declines reflecting production interruptions or other factors could result in increases in unit production costs which could result in substantial losses and weaken our financial condition.
Cancellations or delays of orders by our customers may adversely affect our business and the sophistication and buying power of our customers could have a negative impact on profits
During the fiscal year ended May 30, 2021, sales to the Company’s top five customers accounted for approximately 49% of total revenue of the Company, with the top two customers from the Curation Foods segment, Costco Corporation and Walmart, Inc. accounting for approximately 16% and 15%, respectively, of total revenues of the Company. We expect that, for the foreseeable future, a limited number of customers may continue to account for a substantial portion of our revenues. We may experience changes in the composition of our customer base as we have experienced in the past. The reduction, delay or cancellation of orders from one or more major customers for any reason or the loss of one or more of our major customers could materially and adversely affect our business, operating results, and financial condition. In addition, since some of the products processed by Curation Foods and Lifecore are sole sourced to customers, our operating results could be adversely affected if one or more of our major customers were to develop other sources of supply. Our current customers may not continue to place orders, orders by existing customers may be canceled or may not continue at the levels of previous periods, or we may not be able to obtain orders from new customers.
Our customers, such as supermarkets, warehouse clubs, and food distributors, have continued to consolidate, resulting in fewer customers on which we can rely for business. These consolidations, the growth of supercenters, and the growth of e-commerce customers have produced large, sophisticated customers with increased buying power and negotiating strength who are more capable of resisting price increases and can demand lower pricing, increased promotional programs, or specialty tailored products. In addition, larger retailers have the scale to develop supply chains that permit them to operate with reduced inventories or to develop and market their own retailer brands. These customers may also in the future use more of their shelf space, currently used for our products, for their store brand products. We continue to implement initiatives to counteract these pressures. However, if the larger size of these customers results in additional negotiating strength and/or increased private label or store brand competition, our profitability could decline.
Consolidation also increases the risk that adverse changes in our customers’ business operations or financial performance will have a corresponding material adverse effect on us. For example, as noted above, if our customers cannot access sufficient funds or financing, then they may delay, decrease, or cancel purchases of our products, or delay or fail to pay us for previous purchases.
Our sale of some products may expose us to product liability claims
The testing, manufacturing, marketing, and sale of the products we develop involve an inherent risk of allegations of product liability, including foodborne illness. If any of our products are determined or alleged to be contaminated or defective or to have caused an illness, injury or harmful accident to an end-customer, we could incur substantial costs in responding to complaints or litigation regarding our products and our product brand image could be materially damaged. Such events may have a material adverse effect on our business, operating results and financial condition. In addition, we may be required to participate in product recalls or we may voluntarily initiate a recall as a result of various industry or business practices or the need to maintain good customer relationships.

9

Table of Contents
Although we have taken and intend to continue to take what we consider to be appropriate precautions to minimize exposure to product liability claims, we may not be able to avoid significant liability. We currently maintain product liability insurance. While we think the coverage and limits are consistent with industry standards, our coverage may not be adequate or may not continue to be available at an acceptable cost, if at all. A product liability claim, product recall or other claim with respect to uninsured liabilities or in excess of insured liabilities could have a material adverse effect on our business, operating results and financial condition.

We are subject to increasing competition in the marketplace

Competitors may succeed in developing alternative technologies and products that are more effective, easier to use or less expensive than those which have been or are being developed by us or that would render our technology and products obsolete and non-competitive. We operate in highly competitive and rapidly evolving fields, and new developments are expected to continue at a rapid pace. Competition from large food products, industrial, medical and pharmaceutical companies is expected to be intense. In addition, the nature of our collaborative arrangements may result in our corporate partners and licensees becoming our competitors. Many of these competitors have substantially greater financial and technical resources and production and marketing capabilities than we do, and may have substantially greater experience in conducting clinical and field trials, obtaining regulatory approvals and manufacturing and marketing commercial products.

The food industry is highly competitive, and further consolidation in the industry would likely increase competition. Our principal competitors have substantial financial, marketing, and other resources. Increased competition can reduce our sales due to loss of market share or the need to reduce prices to respond to competitive and customer pressures. Competitive pressures also may restrict our ability to increase prices, including in response to commodity and other cost increases. We sell branded, private brand, and customized food products, as well as commercially branded foods. Our branded products have an advantage over private brand products primarily due to advertising and name recognition, although private brand products typically sell at a discount to those of branded competitors. In addition, when branded competitors focus on price and promotion, the environment for private brand producers becomes more challenging because the price difference between private brand products and branded products may become less significant. In most product categories, we compete not only with other widely advertised branded products, but also with other private label and store brand products that are generally sold at lower prices. A strong competitive response from one or more of our competitors to our marketplace efforts, or a consumer shift towards more generic, lower-priced, or other value offerings, could result in us reducing pricing, increasing marketing or other expenditures, or losing market share. Our margins and profits could decrease if a reduction in prices or increased costs are not counterbalanced with increased sales volume.

In addition, substantial growth in e-commerce has encouraged the entry of new competitors and business models, intensifying competition by simplifying distribution and lowering barriers to entry. The expanding presence of e-commerce retailers has impacted, and may continue to impact, consumer preferences and market dynamics, which in turn may negatively affect our sales or profits.
We must identify changing consumer preferences and develop and offer food products to meet their preferences
Consumer preferences evolve over time and the success of our food products depends on our ability to identify the tastes and dietary habits of consumers and to offer products that appeal to their preferences, including concerns of consumers regarding health and wellness, obesity, product attributes, and ingredients. Introduction of new products and product extensions requires significant development and marketing investment. If our products fail to meet consumer preferences, or we fail to introduce new and improved products on a timely basis, then the return on that investment will be less than anticipated and our strategy to grow sales and profits with investments in acquisitions, marketing, and innovation will be less successful.
Our operations are subject to regulations that directly impact our business
Our products and operations are subject to governmental regulation in the United States and foreign countries. The manufacture of our products is subject to detailed standards for product development, manufacturing controls, ongoing quality monitoring and analysis, and periodic inspection by regulatory authorities. We may not be able to obtain necessary regulatory approvals on a timely basis or at all. Delays in receipt of or failure to receive approvals or loss of previously received approvals would have a material adverse effect on our business, financial condition and results of operations. A significant portion of Curation Foods’ manufacturing workforce is provided by third-party labor contractors. The Company relies upon these contractors to validate the worker’s immigration status and their eligibility to work in the Company’s facilities, and failure of these contractors’ control processes or our internal control processes could result in Curation Foods not complying with applicable regulations. Although we have no reason to believe that we will not be able to comply with all applicable regulations regarding the manufacture and sale of our products and polymer materials, regulations are always subject to change and depend heavily on
10

Table of Contents
administrative interpretations and the country in which the products are sold. Future changes in regulations or interpretations relating to matters such as safe working conditions, laboratory and manufacturing practices, produce safety, environmental controls, and disposal of hazardous or potentially hazardous substances may adversely affect our business.
Our food operations are subject to regulation by the FDA, FTC, and other governmental entities. Applicable laws and regulations are subject to change from time to time and could impact how we manage the production, labeling, and sale of our food products. We are subject, for example, to FDA compliance and regulations concerning the safety of the food products handled and sold by Curation Foods, and the facilities in which they are packed, processed, and stored. Failure to comply with the applicable regulatory requirements can, among other things, result in:

the issuance of adverse inspectional observations,
Warning or Courtesy Letters,
import refusals,
fines, injunctions, civil penalties, and facility suspensions,
withdrawal of regulatory approvals or registrations,
product recalls and product seizures, including cessation of manufacturing and sales,
operating restrictions, and
criminal prosecution
Compliance with foreign, federal, state, and local laws and regulations is costly and time-consuming. We may be required to incur significant costs to comply with the laws and regulations in the future which may have a material adverse effect on our business, operating results and financial condition.
Our food packaging products are subject to regulation under the FDC Act. Under the FDC Act, any substance that when used as intended may reasonably be expected to become, directly or indirectly, a component or otherwise affect the characteristics of any food may be regulated as a food additive unless the substance is generally recognized as safe. Food packaging materials are generally not considered food additives by the FDA if the products are not expected to become components of food under their expected conditions of use. We consider our breathable membrane product to be a food packaging material not subject to approval by the FDA. We have not received any communication from the FDA concerning our breathable membrane product. If the FDA were to determine that our breathable membrane products are food additives, we may be required to submit a food contact substance notification or food additive petition for approval by the FDA. The food additive petition process, in particular, is lengthy, expensive and uncertain. A determination by the FDA that a food contact substance notification or food additive petition is necessary would have a material adverse effect on our business, operating results and financial condition.
Our Curation Foods business is subject to the Perishable Agricultural Commodities Act (“PACA”). PACA regulates fair trade standards in the fresh produce industry and governs all the products sold by Curation Foods. Our failure to comply with the PACA requirements could among other things, result in civil penalties, suspension or revocation of a license to sell produce, and in the most egregious cases, criminal prosecution, which could have a material adverse effect on our business. In addition, the FTC and other state authorities regulate how we promote and advertise our food products, and we could be the target of claims relating to alleged false or deceptive advertising under federal, state, and local laws and regulations.
Lifecore’s existing products and the products that Lifecore is developing for its customers are considered to be medical devices, drug products, or combination products, and therefore, require clearance or approval by the FDA before commercial sales can be made in the United States. The products also require the approval of foreign government agencies before sales may be made in many other countries. The process of obtaining these clearances or approvals varies according to the nature and use of the product. It can involve lengthy and detailed safety and efficacy data, including clinical studies, as well as extensive site inspections and lengthy regulatory agency reviews. There can be no assurance that any of the clinical studies utilizing product produced by Lifecore for its customers will be authorized to proceed, or if authorized will show safety or effectiveness; that any of the products that Lifecore is producing for its customers that require FDA clearance or approval will obtain such clearance or approval on a timely basis, on terms acceptable to the sponsor company for the purpose of actually marketing the products, or at all; or that following any such clearance or approval previously unknown problems will not result in restrictions on the marketing of the products or withdrawal of clearance or approval.
In addition, most of the existing products being sold by Lifecore and its customers are subject to continued regulation by the FDA, various state agencies and foreign regulatory agencies, which regulate the design, nonclinical and clinical research studies, manufacturing, labeling, distribution, post-marketing product modifications, advertising, promotion, import, export, adverse event and other reporting, and record keeping procedures for such products. Aseptic processing and shared equipment manufacturing require specific quality controls. If we fail to achieve and maintain these controls, we may have to recall product, or may have to reduce or suspend production while we address any deficiencies. Marketing clearances or approvals by regulatory
11

Table of Contents
agencies can be withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial clearance or approval. These agencies can also limit or prevent the manufacture or distribution of Lifecore’s products or change or increase the regulatory requirements applicable to such products. A determination that Lifecore is in violation of such regulations could lead to the issuance of adverse inspectional observations, a warning letter, imposition of civil penalties, including fines, product recalls or product seizures, preclusion of product import or export, a hold or delay in pending product approvals, withdrawal of marketing authorizations, injunctions against product manufacture and distribution, and, in extreme cases, criminal sanctions.
Federal, state and local regulations impose various environmental controls on the use, storage, discharge or disposal of toxic, volatile or otherwise hazardous chemicals and gases used in some of our manufacturing processes. Our failure to control the use of, or to restrict adequately the discharge of, hazardous substances under present or future regulations could subject us to substantial liability, cause us to clean up and incur remediation expenses, or cause our manufacturing operations to be suspended. In addition, changes in environmental regulations may impose the need for additional capital equipment or other requirements.
Any new business acquisition will involve uncertainty relating to integration 
We completed the Yucatan Foods acquisition in December, 2018, and the O acquisition in March, 2017. We have acquired other businesses in the past and may make additional acquisitions in the future. The successful integration of new business acquisitions may require substantial effort from the Company’s management. The diversion of the attention of management and any difficulties encountered in the transition process could have a material adverse effect on the Company’s ability to realize the anticipated benefits of the acquisitions. The successful combination of new businesses also requires coordination of research and development activities, manufacturing, sales and marketing efforts. In addition, the process of combining organizations located in different geographic regions could cause the interruption of, or a loss of momentum in, the Company’s activities. There can be no assurance that the Company will be able to retain key management, technical, sales and customer support personnel, or that the Company will realize the anticipated benefits of any acquisitions, and the failure to do so would have a material adverse effect on the Company’s business, results of operations and financial condition.
We may not be able to achieve acceptance of our new products in the marketplace
Our success in generating significant sales of our products depends in part on our ability and that of our partners and licensees to achieve market acceptance of our new products and technology. The extent to which, and rate at which, we achieve market acceptance, including customer preferences and trends, and penetration of our current and future products is a function of many variables including, but not limited to:
price,
safety,
efficacy,
reliability,
conversion costs,
regulatory approvals,
marketing and sales efforts, and
general economic conditions affecting purchasing patterns
We may not be able to develop and introduce new products and technologies in a timely manner or new products and technologies may not gain market acceptance. We and our partners/customers are in the early stage of product commercialization of certain Intelimer-based specialty packaging, and HA-based products and non-HA products and new oil and vinegar products. We expect that our future growth will depend in large part on our and our partners’/customers’ ability to develop and market new products in our target markets and in new markets. In particular, we expect that our ability to compete effectively with existing food products companies will depend substantially on developing, commercializing, achieving market acceptance of and reducing the cost of producing our products. In addition, commercial applications of some of our temperature switch polymer technology are relatively new and evolving. Our failure to develop new products or the failure of our new products to achieve market acceptance would have a material adverse effect on our business, results of operations and financial condition.

12

Table of Contents
We have a concentration of manufacturing for Curation Foods and Lifecore and may have to depend on third parties to manufacture our products

We have a limited number of manufacturing facilities, all of which use specialized manufacturing equipment to operate our business. Any disruptions in our primary manufacturing operations would reduce our ability to sell our products and would have a material adverse effect on our financial results, and create significant additional costs and inefficiencies if we were required to replace such facilities. Additionally, we may need to consider seeking collaborative arrangements with other companies to manufacture our products. If we become dependent upon third parties for the manufacture of our products, our profit margins and our ability to develop and deliver those products on a timely basis may be adversely affected. In that event, additional regulatory inspections or approvals may be required, and additional quality control measures would need to be implemented. Failures by third parties may impair our ability to deliver products on a timely basis and impair our competitive position. We may not be able to continue to successfully operate our manufacturing operations at acceptable costs, with acceptable yields, and retain adequately trained personnel.

We are subject to the risks of doing business internationally

We are subject to the risks of doing business internationally. We conduct a substantial amount of business with growers and customers who are located outside the United States. We purchase avocados and vegetables from foreign growers and packers, sell products to foreign customers, and operate a production facility in Mexico. In the most recent years, there has been an increase in organized crime in Mexico, and significant changes in the Mexican government, both of which create risk for our business. We are also subject to regulations imposed by the Mexican government and to examinations by the Mexican tax authorities. Significant changes to these government regulations and to assessments by the Mexican tax authorities can have a negative impact on our operations and operating results in Mexico.

Fluctuations in foreign currency exchange rates in Mexico may also adversely affect our operating results. While our operations are predominantly in the U.S., we are exposed to foreign currency exchange rate risk with respect to our sales, expenses, profits, assets and liabilities denominated in the Mexican peso. As a result, our financial performance may be affected by changes in foreign currency exchange rates. Moreover, any favorable or unfavorable impacts to gross profit, gross margin, income from operations or segment operating profit from fluctuations in foreign currency exchange rates are likely to be inconsistent year over year.

Since some of our expenses are paid in Mexican pesos and we sell our production in United States dollars, we are subject to changes in currency values that may adversely affect our results of operations. Our operations in the future could be affected by changes in the value of the Mexican peso against the United States dollar. The appreciation of non-U.S. dollar currencies such as the peso against the U.S. dollar increases expenses and the cost of purchasing capital assets in U.S. dollar terms in Mexico, which can adversely impact our operating results and cash flows. Conversely, depreciation of non-U.S. dollar currencies usually decreases operating costs and capital asset purchases in U.S. dollar terms. The value of cash and cash equivalents, and other monetary assets and liabilities denominated in foreign currencies, also fluctuate with changes in currency exchange rates.

For fiscal year 2021, approximately 17% of our consolidated net revenues were derived from product sales to international customers. A number of risks are inherent in international transactions. International sales and operations may be limited or disrupted by any of the following:

regulatory approval process,
government controls,
export license requirements,
political instability,
price controls,
trade restrictions,
fluctuations in foreign currencies,
changes in tariffs, or
difficulties in staffing and managing international operations.

Foreign regulatory agencies have or may establish product standards different from those in the United States, and any inability on our part to obtain foreign regulatory approvals on a timely basis could have a material adverse effect on our international business, and our financial condition and results of operations. While our foreign sales are currently priced in dollars,
13

Table of Contents
fluctuations in currency exchange rates may reduce the demand for our products by increasing the price of our products in the currency of the countries in which the products are sold. Regulatory, geopolitical and other factors may adversely impact our operations in the future or require us to modify our current business practices.

Our dependence on single-source suppliers and service providers may cause disruption in our operations should any supplier fail to deliver materials

Several of the raw materials we use to manufacture our products are currently purchased from a single source, including some monomers used to synthesize Intelimer polymers, substrate materials for our breathable membrane products, and raw materials for our HA products. In addition, several services that are provided to Curation Foods are obtained from a single provider. Any interruption of our relationship with single-source suppliers or service providers could delay product shipments and materially harm our business. We may experience difficulty acquiring materials or services for the manufacture of our products or we may not be able to obtain substitute vendors on a timely basis or at all. In addition, we may not be able to procure comparable materials at similar prices and terms within a reasonable time, if at all, all of which could materially harm our business.

We depend on our infrastructure to have sufficient capacity to handle our on-going production needs

If our machinery or facilities are damaged or impaired due to natural disasters or mechanical failure, or we lose members of our workforce such that our workforce falls below the levels needed to maintain our business, we may not be able to operate at a sufficient capacity to meet our production needs. This could have a material adverse effect on our business, which could impact our results of operations and our financial condition.

We depend on strategic partners and licenses for future development

Our strategy for development, clinical and field testing, manufacture, commercialization and marketing for some of our current and future products includes entering into various collaborations with corporate partners, licensees, and others. We are dependent on our corporate partners to develop, test, manufacture and/or market some of our products. Although we believe that our partners in these collaborations have an economic motivation to succeed in performing their contractual responsibilities, the amount and timing of resources to be devoted to these activities are not within our control. Our partners may not perform their obligations as expected or we may not derive any additional revenue from the arrangements. Our partners may not pay any additional option or license fees to us or may not develop, market or pay any royalty fees related to products under such agreements. Moreover, some of the collaborative agreements provide that they may be terminated at the discretion of the corporate partner, and some of the collaborative agreements provide for termination under other circumstances. Our partners may pursue existing or alternative technologies in preference to our technology. Furthermore, we may not be able to negotiate additional collaborative arrangements in the future on acceptable terms, if at all, and our collaborative arrangements may not be successful.

Risks Related to Ownership of Our Common Stock

Our future operating results are likely to fluctuate which may cause our stock price to decline

In the past, our results of operations have fluctuated significantly from quarter to quarter and are expected to continue to fluctuate in the future. Curation Foods can be affected by seasonal and weather-related factors which have impacted our financial results in the past due to shortages of essential value-added produce items. Lifecore can be affected by the timing of orders from its relatively small customer base and the timing of the shipment of those orders. Our earnings may also fluctuate based on our ability to collect accounts receivable from customers and notes receivable from growers and on price fluctuations in the fresh vegetable and fruit markets. Other factors that affect our operations include:

our ability and our growers’ ability to obtain an adequate supply of labor,
our growers’ ability to obtain an adequate supply of water,
the seasonality and availability and quantity of our supplies,
our ability to process produce during critical harvest periods,
the timing and effects of ripening,
the degree of perishability,
the effectiveness of worldwide distribution systems,
total worldwide industry volumes,
the seasonality and timing of consumer demand,
14

Table of Contents
foreign currency fluctuations, and
foreign importation restrictions and foreign political risks.

In addition, the COVID-19 pandemic has increased the risk of fluctuations in such factors. As a result of these and other factors, we expect to continue to experience fluctuations in quarterly operating results.

Our stock price may fluctuate in response to various conditions, many of which are beyond our control

The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including the following:

weather-related produce sourcing issues,
technological innovations applicable to our products,
pandemics, epidemics and other natural disasters, including the COVID-19 pandemic,
our attainment of (or failure to attain) milestones in the commercialization of our technology,
our development of new products or the development of new products by our competitors,
new patents or changes in existing patents applicable to our products,
our acquisition of new businesses or the sale or disposal of a part of our businesses,
development of new collaborative arrangements by us, our competitors or other parties,
changes in government regulations, interpretation, or enforcement applicable to our business,
changes in investor perception of our business,
fluctuations in our operating results, and
changes in the general market conditions in our industry.

Fluctuations in our quarterly results may, particularly if unforeseen, cause us to miss projections which might result in analysts or investors changing their valuation of our stock.

We may issue preferred stock with preferential rights that could affect your rights

The issuance of shares of preferred stock could have the effect of making it more difficult for a third-party to acquire a majority of our outstanding stock, and the holders of such preferred stock could have voting, dividend, liquidation and other rights superior to those of holders of our Common Stock.

We have never paid any dividends on our common stock

We have not paid any dividends on our Common Stock since inception and do not expect to in the foreseeable future. Any dividends may be subject to preferential dividends payable on any preferred stock we may issue.

Our corporate organizational documents and Delaware law have anti-takeover provisions that may inhibit or prohibit a takeover of us and the replacement or removal of our management

The anti-takeover provisions under Delaware law, as well as the provisions contained in our corporate organizational documents, may make an acquisition of us more difficult. For example:

our certificate of incorporation includes a provision authorizing our Board of Directors to issue blank check preferred stock without stockholder approval, which, if issued, would increase the number of outstanding shares of our capital stock and could make it more difficult for a stockholder to acquire us;
our certificate of incorporation provides for a dual-class Board of Directors, in which each class will serve for a staggered two-year term;
our certificate of incorporation limits the number of directors that may serve on the Board of Directors without the majority approval of all of the outstanding shares of our common stock;
our amended and restated bylaws require advance notice of stockholder proposals and director nominations;
15

Table of Contents
our Board of Directors has the right to implement additional anti-takeover protections in the future, including stockholder rights plans and other amendments to our organizational documents, without stockholder approval; and
Section 203 of the Delaware General Corporation Law may prevent large stockholders from completing a merger or acquisition of us.

These provisions may prevent a merger or acquisition of us which could limit the price investors would pay for our common stock in the future.

General Risks
Changes to U.S. trade policy, tariff and import/export regulations may have a material adverse effect on our business
Changes in U.S. or international social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment in the territories or countries where we currently sell our products or conduct our business, as well as any negative sentiment toward the U.S. as a result of such changes, could adversely affect our business. For example, the previous U.S. presidential administration instituted or proposed changes in trade policies that include the negotiation or termination of trade agreements, the imposition of higher tariffs on imports into the U.S., economic sanctions on individuals, corporations or countries, and other government regulations affecting trade between the U.S. and other countries where we conduct our business.
As a result of such policy changes of the previous U.S. presidential administration and U.S. government proposals, there may be greater restrictions and economic disincentives on international trade. Tariffs and other changes in U.S. trade policy could trigger retaliatory actions by affected countries, and certain foreign governments have instituted or are considering imposing trade sanctions on certain U.S. goods. Such changes have the potential to adversely impact the U.S. economy or certain sectors thereof, our industry and the global demand for our products, and as a result, could have a material adverse effect on our business, financial condition and results of operations.
We may be exposed to employment related claims and costs that could materially adversely affect our business
We have been subject in the past, and may be in the future, to claims by employees based on allegations of discrimination, negligence, harassment, and inadvertent employment of undocumented workers or unlicensed personnel, and we may be subject to payment of workers’ compensation claims and other similar claims. We could incur substantial costs and our management could spend a significant amount of time responding to such complaints or litigation regarding employee claims, which may have a material adverse effect on our business, operating results and financial condition. In addition, several recent decisions by the United States NLRB have found companies, such as Curation Foods, which use contract employees could be found to be “joint employers” with the staffing firm, which may increase our potential exposure for any such claims from contract employees.
We may be subject to unionization, work stoppages, slowdowns or increased labor costs
None of our U.S. based employees are represented by a union, while our employees in our Tanok, Mexico facility are represented by a local union. However, our employees have the right under the National Labor Relations Act to form or affiliate with a union. If some or all of our workforce were to become unionized and the terms of the collective bargaining agreement were significantly different from our current compensation arrangements, it could increase our costs and adversely impact our profitability. Moreover, participation in labor unions could put us at increased risk of labor strikes and disruption of our operations.
We are dependent on our key employees and if one or more of them were to leave, we could experience difficulties in replacing them, or effectively transitioning their replacements and our operating results could suffer
The success of our business depends to a significant extent on the continued service and performance of a relatively small number of key senior management, technical, sales, and marketing personnel. The loss of any of our key personnel for an extended period may cause hardship for our business. In addition, competition for senior level personnel with knowledge and experience in our different lines of business is intense. If any of our key personnel were to leave, we would need to devote substantial resources and management attention to replace them. As a result, management attention may be diverted from managing our business, and we may need to pay higher compensation to replace these employees.
16

Table of Contents
Our reputation and business may be harmed if our computer network security or any of the databases containing our trade secrets, proprietary information or the personal information of our employees are compromised
Cyber-attacks or security breaches could compromise our confidential business information, cause a disruption in the Company’s operations or harm our reputation. We maintain numerous information assets, including intellectual property, trade secrets, banking information and other sensitive information critical to the operation and success of our business on computer networks, and such information may be compromised in the event that the security of such networks is breached. We also maintain confidential information regarding our employees and job applicants, including personal identification information. The protection of employee and company data in the information technology systems we utilize (including those maintained by third-party providers) is critical. Despite the efforts by us to secure computer networks utilized for our business, security could be compromised, confidential information, such as Company information assets and personally identifiable employee information, could be misappropriated, or system disruptions could occur.
In addition, we may not have the resources or technical sophistication to anticipate or prevent rapidly evolving types of cyberattacks. Attacks may be targeted at us, our customers, or others who have entrusted us with information. Actual or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. Advances in computer capabilities, new technological discoveries or other developments may result in the technology used by us to protect sensitive Company data being breached or compromised. Furthermore, actual or anticipated cyberattacks or data breaches may cause significant disruptions to our network operations, which may impact our ability to deliver shipments or respond to customer needs in a timely or efficient manner.
Data and security breaches could also occur as a result of non-technical issues, including an intentional or inadvertent breach by our employees or by persons with whom we have commercial relationships that result in the unauthorized release of confidential information related to our business or personal information of our employees. Any compromise or breach of our computer network security could result in a violation of applicable privacy and other laws, costly investigations and litigation, and potential regulatory or other actions by governmental agencies. As a result of any of the foregoing, we could experience adverse publicity, the compromise of valuable information assets, loss of sales, the cost of remedial measures and/or significant expenditures to reimburse third parties for resulting damages, any of which could adversely impact our brand, our business and our results of operations. 
We may be unable to adequately protect our intellectual property rights or may infringe intellectual property rights of others
We may receive notices from third parties, including some of our competitors, claiming infringement by our products of their patent and other proprietary rights. Regardless of their merit, responding to any such claim could be time-consuming, result in costly litigation and require us to enter royalty and licensing agreements which may not be offered or available on terms acceptable to us. If a successful claim is made against us and we fail to develop or license a substitute technology, we could be required to alter our products or processes and our business, results of operations or financial position could be materially adversely affected. Our success depends in large part on our ability to obtain patents, maintain trade secret protection, and operate without infringing on the proprietary rights of third parties. Any pending patent applications we file may not be approved and we may not be able to develop additional proprietary products that are patentable. Any patents issued to us may not provide us with competitive advantages or may be challenged by third parties. Patents held by others may prevent the commercialization of products incorporating our technology. Furthermore, others may independently develop similar products, duplicate our products or design around our patents.
The global economy is experiencing continued volatility, which may have an adverse effect on our business
In recent years, the U.S. and international economy and financial markets have experienced significant volatility due to uncertainties related to the availability of credit, energy prices, the COVID-19 pandemic, national elections and other political events, difficulties in the banking and financial services sectors, diminished market liquidity, and geopolitical conflicts. Ongoing volatility in the economy and financial markets could further lead to reduced demand for our products, which in turn, would reduce our revenues and adversely affect our business, financial condition and results of operations. In particular, volatility in the global markets have resulted in softer demand and more conservative purchasing decisions by customers, including a tendency toward lower-priced products, which could negatively impact our revenues, gross margins and results of operations. In addition to a reduction in sales, our profitability may decrease because we may not be able to reduce costs at the same rate as our sales decline. We cannot predict the ultimate severity or length of the current period of volatility, or the timing or severity of future economic or industry downturns.
17

Table of Contents
Given the current uncertain economic environment, and the COVID-19 pandemic, our customers, suppliers, and partners may have difficulties obtaining capital at adequate or historical levels to finance their ongoing business and operations, which could impair their ability to make timely payments to us. This may result in lower sales and/or inventory that may not be saleable or may result in bad debt expenses for us. A worsening of the economic environment or continued or increased volatility of the U.S. economy, including increased volatility in the credit markets, could adversely impact our customers’ and vendors’ ability or willingness to conduct business with us on the same terms or at the same levels as they have historically. Further, this economic volatility and uncertainty about future economic conditions makes it challenging for Landec to forecast its operating results, make business decisions, and identify the risks that may affect its business, sources and uses of cash, financial condition and results of operations.
Litigation costs and the outcome of litigation could have a material adverse effect on our business
From time to time we may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, employment matters, safety standards, product liability, security of customer and employee personal information, contractual relations with vendors, marketing and infringement of trademarks and other intellectual property rights. In addition, as described elsewhere in this report, the COVID-19 pandemic, and our responses thereto, may subject us to further litigation, including with respect to employment matters, contract disputes, and other matters. Litigation to defend ourselves against claims by third parties, or to enforce any rights that we may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of operations or cash flows.
Lapses in disclosure controls and procedures or internal control over financial reporting could materially and adversely affect the Company’s operations, profitability or reputation
Lapses or deficiencies in disclosure controls and procedures or in our internal control over financial reporting may occur from time to time. There can be no assurance that our disclosure controls and procedures will be effective in preventing a material weakness or significant deficiency in internal control over financial reporting from occurring in the future. Any such lapses or deficiencies may materially and adversely affect our business and results of operations or financial condition, restrict our ability to access the capital markets, require us to expend resources to correct the lapses or deficiencies, which could include the restating of previously reported financial results, expose us to regulatory or legal proceedings, harm our reputation, or otherwise cause a decline in investor confidence.

Item 1B.    Unresolved Staff Comments
None.

Item 2.    Properties
As of May 30, 2021, the Company owned or leased the following principle physical properties:
LocationBusiness SegmentOwnershipFacilities
Guadalupe, CACuration FoodsOwned199,000 square feet of office space, manufacturing and cold storage
Chaska, MNLifecore Owned148,200 square feet of office, laboratory and manufacturing space
Silao, Guanajuato, MexicoCuration FoodsLeased97,000 square feet of office and manufacturing space
Chaska, MNLifecoreLeased80,950 square feet of office, manufacturing and warehouse space
Bowling Green, OHCuration FoodsOwned55,900 square feet of office space, manufacturing and cold storage
Santa Maria, CACuration FoodsLeased36,300 square feet of office and laboratory space
Chanhassen, MNLifecoreLeased21,384 square feet of warehouse and office space
Petaluma, CACuration FoodsLeased18,400 square feet of office and manufacturing space
Rock Hill, SCCuration FoodsOwned16,400 square feet of cold storage and office space
18

Table of Contents
In addition to the principal physical properties described above, the Company owns or leases a number of other facilities and land in various locations in the United States that are used for manufacturing, cold storage, and administration activities. Leases for these leased facilities expire at various dates through the year 2040. The Company does not anticipate experiencing significant difficulty in retaining occupancy of any of our manufacturing, laboratory, cold storage, or office facilities through lease renewals prior to expiration or through month-to-month occupancy, or in replacing them with equivalent facilities. We believe our existing facilities, both owned and leased, are in good condition and suitable for the conduct of our business.

Item 3.    Legal Proceedings
The information contained in Note 10 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K is incorporated herein by reference.

Item 4.    Mine Safety Disclosures
Not applicable.
19

Table of Contents
PART II

Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
The Common Stock is traded on The NASDAQ Global Select Market under the symbol “LNDC”.
Holders
As of July 26, 2021, there were approximately 46 holders of record of our common stock. Since certain holders are listed under their brokerage firm’s names, the actual number of stockholders is higher.
Dividends
The Company has not paid any dividends on the Common Stock since its inception. The Company presently intends to retain all future earnings, if any, for its business and does not anticipate paying cash dividends on its Common Stock in the foreseeable future.
Issuer Purchases of Equity Securities
For the twelve months ended May 30, 2021, there have been no shares repurchased by the Company. The Company may still repurchase up to $3.8 million of the Company’s Common Stock under the Company’s stock repurchase plan announced on July 14, 2010.
Recent Sales of Unregistered Equity Securities
The Company did not sell any unregistered equity securities during the twelve months ended May 30, 2021.

Item 6.    Selected Financial Data
Not applicable.

Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with the Company’s Consolidated Financial Statements contained in Item 8 of this report. Except for the historical information contained herein, the matters discussed in this report are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Potential risks and uncertainties include, without limitation, those mentioned in this report and, in particular, the factors described in Item 1A. “Risk Factors”. Please see “Note About Forward Looking Statements”.

Overview
Landec Corporation and its subsidiaries (“Landec”, the “Company”, “we” or “us”) design, develop, manufacture, and sell differentiated products for food and biomaterials markets, and license technology applications to partners. Landec has three reportable business segments – Curation Foods, Lifecore, and Other which are described below. Landec’s biomedical company, Lifecore Biomedical®, is a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of sterile, injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 36 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.
Landec’s natural food company, Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology. Also included in the Curation Foods segment operating results are the dividends and Landec’s share of the change in the fair market value of the Company’s 26.9% investment ownership of Windset, a leading edge grower of hydroponically-grown produce.
20

Table of Contents
Included in the Other segment is Corporate, which includes corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income and income tax expenses.
Strategy
The Company’s strategy is to maximize the value of our business portfolio by improving operating margins at Curation Foods, investing in growth to drive momentum at Lifecore while driving profitable growth across the organization with consumer insights driven innovation. Each of our business segments are in different life stages and have clear strategic priorities.
Lifecore
Lifecore is the Company’s FDA approved CDMO business, which is focused on driving profitable growth with product development and manufacturing of sterile injectable products. Lifecore seeks to expand its presence in the CDMO marketplace by partnering with biopharmaceutical and biotechnology companies to bring their unique therapies to market. Lifecore’s goal of continuing success will be to execute on its three strategic priorities:
1) Managing Business Development Pipeline: Accelerate product development activities for small and large biopharmaceutical and biotechnology companies in various stages of the product lifecycle, spanning clinical development stage to commercialization, which aligns with the business’ overall product development strategy.
2) Maximizing Capacity: Meet customer demand by maximizing capacity in the syringe and vial multi-purpose filler production line to significantly increase the number of products produced.
3) Advancing Product Commercialization: Continue to seek out opportunities to advance customers’ late-stage product development activities by supporting their clinical programs and commercial process scale-up activities.
Curation Foods
Curation Foods, the Company’s natural food business, is focused on transforming its business to improve operational performance. The Company launched Project SWIFT which aims to strengthen Curation Foods by simplifying the business. The Company believes that the decisive actions of Project SWIFT will help improve the Company’s operating cost structure, enhance profitability, and strengthen its balance sheet with an overall aim to deliver long-term value to shareholders. Curation Foods intends to continue to deliver high levels of product quality and safety, while successfully executing on its customer, grower, and partner commitments. Project SWIFT will continue to be implemented throughout fiscal 2022, with three strategic priorities designed to improve Curation Foods’ overall financial performance and profitability:

1) Network & Operational Optimization: Streamline the organization to maximize efficiency and productivity by continuous improvement in plant operations with lean manufacturing practices. This included the consolidation and centralization of Curation Foods various offices into its Innovation Center headquarters in Santa Maria, California in fiscal 2020.
2) Focus on Strategic Assets: Simplify the business by divesting non-core assets. In fiscal 2020 the Company initiated the strategic sale process of the Company’s Ontario, California salad dressing manufacturing facility, which had yet to become operational and a review of strategic options for its legacy core vegetable bag and tray business. In the first quarter of fiscal year 2021, the Company sold its interest in Ontario for net proceeds of $4.9 million. In June 2020 the Company began exploring opportunities for the divestiture of its underutilized Hanover manufacturing facility, and during the second quarter of fiscal year 2021, the Company sold the Hanover building and assets related thereto for net proceeds of $8.0 million.
3) Organizational Redesign: Redesigning the organization so that it is the appropriate size for the Company’s future direction. In fiscal 2021, the Company focused on redesigning strategic initiatives, developed and elevated internal talent and reduced overall headcount to improve efficiencies.
During May 2021 we entered into a transportation management, warehousing, and transportation services agreement with Castellini Company, LLC to outsource Curation Foods’ fresh packaged salads and vegetables logistics management, including transportation, warehousing and distribution. We expect to benefit from engaging with a strategic logistics partner to increase our distribution reach into markets that we do not currently serve, improve efficiency by increased distribution frequency in existing markets and reduce our overall operating costs, thereby bringing greater value to our stockholders.
21

Table of Contents
The COVID-19 Pandemic
There are many uncertainties regarding the COVID-19 pandemic, including the scope of scientific and health issues, the anticipated duration of the pandemic, and the extent of local and worldwide social, political, and economic disruption it may cause. The COVID-19 pandemic has had and we believe will continue to have significant adverse impacts on many aspects of the Company’s operations, directly and indirectly, including with respect to sales, customer behaviors, business and manufacturing operations, inventory, the Company’s employees, and the market generally, and the scope and nature of these impacts continue to evolve each day. The Company expects to continue to assess the evolving impact of the COVID-19 pandemic, and intends to continue to make adjustments to its responses accordingly.

Critical Accounting Policies and Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes to the Consolidated Financial Statements. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; loss contingencies, sales returns and credit losses; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived assets (including intangible assets) and inventory; the valuation of investments; the valuation and recognition of stock-based compensation; and the valuation and recognition of contingent liabilities.
These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve, and are subject to change from period to period. The actual results may differ from management’s estimates. Our accounting policies are more fully described in “Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies” to our consolidated financial statements. Management has discussed the development and selection of these critical accounting policies and estimates with our Board of Directors.
Revenue Recognition
The Company follows the five step, principles-based model to recognize revenue upon the transfer of promised goods or services to customers and in an amount that reflects the consideration for which the Company expects to be entitled in exchange for those goods or services. Revenue, net of estimated allowances and returns, is recognized when or as the Company satisfies its performance obligations under a contract and control of the product is transferred to the customer.

Curation Foods

Curation Foods’ standard terms of sale are generally included in its contracts and purchase orders. Revenue is recognized at the time shipment is made or upon delivery as control of the product is transferred to the customer. Shipping and other transportation costs charged to customers are recorded in both revenue and cost of goods sold. Curation Foods has elected to account for shipping and handling as fulfillment activities, and not as a separate performance obligation. Curation Foods’ standard payment terms with its customers generally range from 30 days to 90 days. Certain customers may receive cash-based incentives (including volume rebates, discounts, and promotions), which are accounted for as variable consideration to Curation Foods’ performance obligations. Curation Foods estimates these sales incentives based on the expected amount to be provided to its customers and reduces revenue recognized towards its performance obligations. The Company has not historically had and does not anticipate significant changes in its estimates for variable consideration.

Lifecore

Lifecore generates revenue from two integrated activities: CDMO and fermentation. CDMO is comprised of aseptic and development services. Lifecore’s standard terms of sale are generally included in its contracts and purchase orders. Shipping and other transportation costs charged to customers are recorded in both revenue and cost of goods sold. Lifecore has elected to account for shipping and handling as fulfillment activities, and not as a separate performance obligation. Lifecore’s standard payment terms with its customers generally range from 30 days to 60 days.

22

Table of Contents
Aseptic

Lifecore provides aseptic formulation and filling of syringes and vials with precisely formulated medical grade HA and non-HA materials for injectable products used for medical purposes. In instances where our customers contract with us to aseptically fill syringes or vials with our HA, the goods are not distinct in the context of the contract. Lifecore recognizes revenue for these products at the point in time when legal title to the product is transferred to the customer, which is at the time that shipment is made or upon delivery of the product.

Development Services

Lifecore provides product development services to assist its customers in obtaining regulatory approval for the commercial sale of their drug product. These services include activities such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation and production of materials for use within clinical studies. The Company’s customers benefit from the expertise of its scientists who have extensive experience performing such tasks.

Each of the promised goods and services are not distinct in the context of the contract as the goods and services are highly interdependent and interrelated. The services described above are significantly affected by each other because Lifecore would not be able to fulfill its promise by transferring each of the goods or services independently.

Revenues generated from development services arrangements are recognized over time as Lifecore is creating an asset without an alternate use as it is unique to the customer. Furthermore, the Company has an enforceable right to payment for the performance completed to date for its costs incurred in satisfying the performance obligation plus a reasonable profit margin. For each of the development activities performed by Lifecore as described above, labor is the primary input (i.e., labor costs represent the majority of the costs incurred in the completion of the services). The Company determined that labor hours are the best measure of progress as it most accurately depicts the effort extended to satisfy the performance obligation over time.

Fermentation

Lifecore manufactures and sells pharmaceutical-grade sodium hyaluronate (“HA”) in bulk form to its customers. The HA produced is distinct as customers are able to utilize the product provided under HA supply contracts when they obtain control. Lifecore recognizes revenue for these products at the point in time when legal title to the product is transferred to the customer, which is at the time that shipment is made or upon delivery of the product to our customer.

Impairment Review of Goodwill and Indefinite-Lived Intangible Asset
The Company tests its goodwill and trademarks with indefinite lives annually for impairment in the fiscal fourth quarter or earlier if there are indications during a different interim period that these assets may have become impaired.
On a quarterly basis, the Company considers the need to update its most recent annual tests for possible impairment of its indefinite-lived intangible assets and goodwill, based on management’s assessment of changes in its business and other economic factors since the most recent annual evaluation. Such changes, if significant or material, could indicate a need to update the most recent annual tests for impairment of the indefinite-lived intangible assets during the current period. The results of these tests could lead to write-downs of the carrying values of these assets in the current period.
With respect to goodwill, the Company has the option to first assess qualitative factors such as macro-economic conditions, industry and market environment, cost factors, overall financial performance of the Company, cash flow from operating activities, market capitalization, litigation, and stock price. If the result of a qualitative test indicates a potential for impairment of a reporting unit, a quantitative test is performed. The quantitative test compares the carrying amount of a reporting unit that includes goodwill to its fair value. The Company determines the fair value using both an income approach and a market approach. Under the income approach, fair value is determined based on estimated future cash flows, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of the Company and the rate of return an outside investor could expect to earn. Under the market-based approach, information regarding the Company is utilized along with publicly available industry information to determine earnings multiples that are used to value the Company. A goodwill impairment loss is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit.
To determine the fair value of a reporting unit as part of its quantitative test, the Company uses a discounted cash flow ("DCF") method under the income approach, as it believes that this approach is the most reliable indicator of the fair value of its
23

Table of Contents
businesses and the fair value of their future earnings and cash flows. Under this approach, which requires significant judgments, the Company estimates the future cash flows of each reporting unit and discounts these cash flows at a rate of return that reflects their relative risk. The cash flows used in the DCF method are consistent with those the Company uses in its internal planning, which gives consideration to actual business trends experienced, and the broader business strategy for the long term. The other key estimates and factors used in the DCF method include, but are not limited to, future volumes, net sales and expense growth rates, and gross margin and gross margin growth rates. Changes in such estimates or the application of alternative assumptions could produce different results.
For trademarks and other intangible assets with indefinite lives, the Company performs a quantitative analysis to test for impairment. When a quantitative test is performed, the estimated fair value of an asset is compared to its carrying amount. If the carrying amount of such asset exceeds its estimated fair value, an impairment charge is recorded for the difference between the carrying amount and the estimated fair value. The Company uses the income approach to estimate the fair value of its trademarks. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows as well as the appropriate discount rates applied to those cash flows to determine fair value. Changes in such estimates or the use of alternative assumptions could produce different results.
During fiscal year 2020, the Company recorded an impairment charge of $1.1 million and $3.5 million related to its O and Yucatan Foods trademarks, respectively. The Company also recorded an impairment charge of $5.2 million and $2.7 million related to its O and Yucatan Foods goodwill, respectively. The O impairment charges were primarily a result of the recently updated (lowered) financial outlook for the O reporting unit, related to a recent shift in strategic focus within the Curation Foods business segment. The Yucatan Foods' impairment charges were primarily a result of an increase in the Yucatan Foods carrying value and an in increase in the discount rate, as a result of uncertainty in forecasting the effects of COVID-19 and general economic uncertainties. These impairment charges are included in the line item “impairment of goodwill and intangible assets” on the Consolidated Statements of Operations, and both are in the Curation Foods business segment. There was no impairment charge during fiscal year 2021.

Income Taxes
The Company accounts for income taxes in accordance with accounting guidance which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. The Company maintains valuation allowances when it is likely that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances from period to period are included in the Company’s income tax provision in the period of change. In determining whether a valuation allowance is warranted, the Company takes into account such factors as prior earnings history, expected future earnings, unsettled circumstances that, if unfavorably resolved, would adversely affect utilization of a deferred tax asset, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset.
In addition to valuation allowances, the Company establishes accruals for uncertain tax positions. The tax-contingency accruals are adjusted in light of changing facts and circumstances, such as the progress of tax audits, case law and emerging legislation. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. The Company’s effective tax rate includes the impact of tax-contingency accruals as considered appropriate by management.
A number of years may elapse before a particular matter, for which the Company has accrued, is audited and finally resolved. The number of years with open tax audits varies by jurisdiction. While it is often difficult to predict the final outcome or the timing of resolution of any particular tax matter, the Company believes its tax-contingency accruals are adequate to address known tax contingencies. Favorable resolution of such matters could be recognized as a reduction to the Company’s effective tax rate in the year of resolution. Unfavorable settlement of any particular issue could increase the Company's effective tax rate in the year of resolution. Any resolution of a tax issue may require the use of cash in the year of resolution. The Company’s tax-contingency accruals are recorded in Other accrued liabilities in the accompanying Consolidated Balance Sheets.

Recent Accounting Pronouncements
Refer to Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies in the notes to our consolidated financial statements for a description of recent accounting pronouncements and our expectation of their impact, if any, on our results of operations and financial condition.

24

Table of Contents
Results of Operations
Revenues:
Curation Foods revenues consist of revenues generated from (1) the sale of specialty packaged fresh-cut and whole processed vegetable products and salads that are washed and packaged in most cases in the Company’s proprietary BreatheWay packaging and sold primarily under the Eat Smart brand and various private labels, (2) O olive oils and wine vinegars, and (3) Yucatan and Cabo Fresh branded guacamole and avocado products. In addition, the Curation Foods reportable business segment includes the revenues generated from the sale of BreatheWay packaging to license partners.
Lifecore generates revenues from the development and manufacture of pharmaceutical-grade sodium hyaluronate (“HA”) products and providing contract development and aseptic manufacturing services to customers. Lifecore generates revenues from two integrated activities: (1) CDMO and (2) fermentation.

(In thousands, except percentages)Year EndedChangeYear EndedChange
 May 30, 2021May 31, 2020Amount%May 31, 2020May 26, 2019Amount%
Curation Foods$446,074 $504,533 $(58,459)(12)%$504,533 $481,686 $22,847 5%
Lifecore 98,087 85,833 12,254 14%85,833 75,873 9,960 13%
Total Revenues$544,161 $590,366 $(46,205)(8)%$590,366 $557,559 $32,807 6%

Curation Foods

The decrease in Curation Foods’ revenues for fiscal year 2021 compared to fiscal year 2020 was primarily due to a $57.7 million decrease in revenues in the fresh packaged salads and vegetables product line, which was primarily due to (1) a $35.5 million planned shift away from non-strategic revenue streams, including packaged vegetables in bags and trays, (2) an $11.6 million decrease in green bean revenues driven by a decrease in demand from food service customers during the COVID-19 pandemic, and (3) a $6.9 million decrease in salad revenues driven by a decrease in demand during the COVID-19 pandemic.

The increase in Curation Foods’ revenues for fiscal year 2020 compared to fiscal year 2019, was primarily due to (1) the addition of Yucatan Foods, which was acquired on December 1, 2018, that contributed a comparative increase of $34.9 million in revenues, (2) a $12.7 million increase in salad revenues, and (3) a $3.1 million increase in BreatheWay revenues. These increases were partially offset by a $17.3 million planned decrease in revenues from packaged vegetables in bags and trays, and a $9.0 million decrease in green bean revenues due to weather-related events that resulted in lower yields.

Lifecore

The increase in Lifecore’s revenues for fiscal year 2021 compared to fiscal year 2020 was primarily due to a $10.5 million increase in CDMO revenues resulting from increased demand from existing customers that drove an increase in aseptic filling commercial shipments, and a $1.7 million increase in fermentation sales due to higher sales to existing customers.
The increase in Lifecore’s revenues for fiscal year 2020 compared to fiscal year 2019 was primarily due to a $10.4 million increase in CDMO revenues from an increase in development services activities and an increase in aseptic filling commercial shipments, primarily due to higher sales to existing customers, partially offset by a $0.4 million decrease in fermentation sales to existing customers.
Gross Profit:
There are numerous factors that can influence gross profit including product mix, customer mix, manufacturing costs, volume, sales discounts and charges for excess or obsolete inventory, to name a few. Many of these factors influence or are interrelated with other factors. The Company includes in cost of sales all of the following costs: raw materials (including produce, seeds, packaging, syringes and fermentation and purification supplies), direct labor, overhead (including indirect labor, depreciation, and facility-related costs), and shipping and shipping-related costs.

25

Table of Contents
(In thousands, except percentages)
Year Ended
Change
Year Ended
Change
 
May 30, 2021May 31, 2020
Amount
%
May 31, 2020May 26, 2019
Amount
%
Curation Foods
$43,209 $42,105 $1,104 3%$42,105 $49,305 $(7,200)(15)%
Lifecore
38,265 32,883 5,382 16%32,883 31,698 1,185 4%
Total Gross Profit
$81,474 $74,988 $6,486 9%$74,988 $81,003 $(6,015)(7)%

Curation Foods

The increase in gross profit for the Curation Foods business for fiscal year 2021 compared to fiscal year 2020 was primarily due to an increase in gross profits from avocado products driven by the sale of products in fiscal 2021 produced with lower cost avocados than those used for products sold in fiscal 2020, which was partially offset by (1) the decrease in gross profits primarily driven by the decrease in revenues from our planned shift away from non-strategic fresh packaged salads and vegetables segment revenue streams (primarily packaged vegetables in bags and trays), (2) the decrease in gross profits driven by a decrease in royalty revenue of $1.6 million due to nonrecurring royalty transactions, and (3) business interruption insurance recoveries received in fiscal year 2020.
The decrease in gross profit for the Curation Foods business for fiscal year 2020 compared to fiscal year 2019 was primarily due to (1) the sale of avocado products that were produced during the fourth quarter of fiscal 2019 and first quarter of fiscal 2020 when the costs of avocados were substantially higher than current production costs, (2) adverse weather-related events impacting raw material supply during fiscal year 2020, and (3) lower gross profit driven by a planned de-emphasis of packaged vegetables in bags and trays. These decreases were partially offset by an increase in gross profits from the increase in BreatheWay revenues.
Lifecore
The increase in Lifecore’s gross profit for fiscal year 2021 compared to fiscal year 2020 was primarily due to a 14% increase in revenues, as well as a favorable product mix change in fiscal year 2021. As a result, Lifecore’s gross margin increased to 39.0% in fiscal year 2021 from 38.3% in fiscal year 2020.
The increase in Lifecore’s gross profit for fiscal year 2020 compared to fiscal year 2019 was primarily due to a 13% increase in revenues partially offset by temporary manufacturing inefficiencies in the fourth quarter of fiscal year 2020 associated with new safety protocols primarily due to the COVID-19 pandemic. As a result, Lifecore's gross margin decreased to 38.3% in fiscal year 2020 from 41.8% in fiscal year 2019.

Operating Expenses:
Research and Development (R&D)
R&D expenses consist primarily of product development and commercialization initiatives. R&D expenses in our Curation Foods business are primarily focused on innovating our current product lines and on the Company’s proprietary BreatheWay membranes used for packaging produce, with a focus on extending the shelf-life of sensitive vegetables and fruit. In the Lifecore business, the R&D expenses are focused on new products and applications for HA-based and non-HA biomaterials. For Other, the R&D expenses are primarily focused on creating and developing new innovative lines of products.

(In thousands, except percentages)
Year Ended
Change
Year Ended
Change
 
May 30, 2021May 31, 2020
Amount
%
May 31, 2020May 26, 2019
Amount
%
Curation Foods
$4,064 $5,142 $(1,078)(21)%$5,142 $5,444 $(302)(6)%
Lifecore
6,157 5,910 247 4%5,910 5,085 825 16%
Other
— 47 (47)(100)%47 937 (890)(95)%
Total R&D
$10,222 $11,099 $(877)(8)%$11,099 $11,466 $(367)(3)%

26

Table of Contents
The decrease in R&D expenses for fiscal year 2021 compared to fiscal year 2020 was primarily due to (1) a $1.1 million decrease in our Curation Foods segment primarily driven by a decrease in consulting and other professional services related to a packaging redesign and brand restage, partially offset by (2) an increase in Lifecore’s R&D expenses primarily due to higher salary and benefit expenses, including increased headcount.

The decrease in R&D expenses for fiscal year 2020 compared to fiscal year 2019 was primarily due to (1) a $0.9 million decrease in our Other segment primarily due to discontinuing most R&D activities at corporate, (2) a $0.3 million decrease in our Curation Foods segment driven by a decrease in legal and other professional services, partially offset by (3) an increase in Lifecore’s R&D expenses primarily due to higher salary and benefit expenses driven by an increase in headcount related to increased development activities.
Selling, General and Administrative ("SG&A")
SG&A expenses consist primarily of sales and marketing expenses associated with Landec’s product sales and services, business development expenses, and staff and administrative expenses.

(In thousands, except percentages)
Year Ended
Change
Year Ended
Change
 May 30, 2021May 31, 2020Amount%May 31, 2020May 26, 2019Amount%
Curation Foods
$38,624 $46,130 $(7,506)(16)%$46,130 $43,828 $2,302 5%
Lifecore
8,305 7,688 617 8%7,688 6,618 1,070 16%
Other
18,435 18,370 65 —%18,370 11,616 6,754 58%
Total SG&A
$65,364 $72,188 $(6,824)(9)%$72,188 $62,062 $10,126 16%

The decrease in SG&A expenses for fiscal year 2021 compared to fiscal year 2020 was primarily due to a $7.5 million decrease at Curation Foods primarily due to cost savings driven by our restructuring efforts associated with Project SWIFT and lower salary and related expenses. These decreases were partially offset by a $0.6 million increase at Lifecore due to increased salary and benefit expenses, including increased headcount.

The increase in SG&A expenses for fiscal year 2020 compared to fiscal year 2019 was due to (1) a $6.8 million increase in our Other segment primarily due to a (a) $6.0 million increase in legal fees related to compliance and other legal matters and (b) a $3.0 million greater reduction of the earn out liability (reduction of SG&A costs) associated with the O acquisition in the same period last year compared to the current period, and (c) a $1.8 million decrease in salaries and related benefits due to a decrease in headcount and bonus expense, (2) a $2.3 million increase in our Curation Foods business primarily due to (a) $3.0 million of increased SG&A at Yucatan Foods, which is primarily due to a full year of SG&A expenses in fiscal 2020 compared to a partial year in fiscal 2019, net of merger and acquisition costs incurred, in the same period last year, (b) the $1.2 million reserve for the receivable from Pacific Harvest, partially offset by, (c) a $1.6 million decrease in consulting fees, most of which was associated with Curation Foods’ cost saving initiatives, and (3) a $1.0 million increase in our Lifecore business SG&A due to higher salary and benefit expenses driven by an increase in headcount.
Impairment of Goodwill and Intangible assets, Legal Settlement Charge, and Restructuring Costs

(In thousands, except percentages)Year EndedChangeYear EndedChange
 May 30, 2021May 31, 2020Amount%May 31, 2020May 26, 2019Amount%
Impairment of Goodwill and Intangible Assets
$— $12,953 $(12,953)(100)%$12,953 $— $12,953 100%
Legal Settlement Charge1,763 — 1,763 100%— — — —%
Restructuring Costs17,621 17,285 336 2%17,285 — 17,285 100%

During fiscal year 2020, the Company recorded an impairment charge of $1.1 million and $3.5 million related to its O and Yucatan Foods trademarks, respectively. The Company also recorded an impairment charge of $5.2 million and $2.7 million related to its O and Yucatan Foods goodwill, respectively. The O impairment charges were primarily a result of the recently updated (lowered) financial outlook for the O reporting unit, related to a recent shift in strategic focus within the Curation Foods business segment. The Yucatan Foods impairment charges were primarily a result of an increase in the Yucatan Foods carrying
27

Table of Contents
value and in increase in discount rate, as a result of uncertainty in forecasting the effects of COVID-19 and general economic uncertainties. These impairment charges are included in the line item “impairment of goodwill and intangible assets” on the Consolidated Statements of Operations, and both are in the Curation Foods business segment. Refer to Note 1 - Impairment Review of Goodwill and Indefinite-Lived Intangible Asset in the notes to our consolidated financial statements for more information.

In fiscal year 2021 the Company executed a settlement agreement related to a legal matter with Pacific Harvest, Inc. and Rancho Harvest, Inc., In connection with the settlement agreement, the Company recorded a $1.8 million charge after considering the total settlement amount and insurance recoveries, and this amount is included in legal settlement charge in the Consolidated Statements of Operations for the fiscal year ended May 30, 2021. Refer to Note 10 - Commitments and Contingencies - Legal Contingencies in the notes to our consolidated financial statements for more information.

During fiscal year 2020, the Company announced a restructuring plan to drive enhanced profitability, focus the business on its strategic assets and redesign the organization to be the appropriate size to compete and thrive. This includes a reduction-in-force, a reduction in leased office spaces and the sale of non-strategic assets. The Company recorded $17.6 million and $17.3 million in fiscal years 2021 and 2020, respectively, related to the restructuring plan. Refer to Note 14 - Restructuring Costs in the notes to our consolidated financial statements for more information.
Other:
(In thousands, except percentages)Year EndedChangeYear EndedChange
 May 30, 2021May 31, 2020Amount%May 31, 2020May 26, 2019Amount%
Dividend Income$1,125 $1,125 $— —%$1,125 $1,650 $(525)(32)%
Interest Income48 103 $(55)(53)%103 145 (42)(29)%
Interest Expense(15,344)(9,603)$(5,741)60%(9,603)(5,230)(4,373)84%
Loss on Debt Refinancing(1,110)— $(1,110)—%— — — —%
Other Income (Expense)(11,689)(4,395)$(7,294)166%(4,395)1,600 (5,995)N/M
Income Tax (Expense) Benefit
7,801 13,116 $(5,315)(41)13,116 (1,518)14,634 N/M

Dividend Income
Dividend income is derived from the dividends accrued during each period on the Company’s previously held $15.0 million Senior A and $7.0 million Senior B preferred stock investment in Windset, which each yielded a cash dividend of 7.5% annually. There was no change in dividend income for the fiscal year ended May 30, 2021 compared to May 31, 2020. The decrease in dividend income for fiscal year 2020 compared to fiscal year 2019 was due to the sale of the Company’s previously held $7.0 million Senior B preferred stock to Windset in the fourth quarter of fiscal year 2019.

Subsequent to fiscal year end 2021, the Company sold its remaining investment in Windset on June 1, 2021.
Interest Income
The decrease in interest income in fiscal year 2021 compared to fiscal year 2020, and 2020 compared to fiscal 2019 was not significant.
Interest Expense

The increase in interest expense during fiscal year 2021 compared to fiscal year 2020 was primarily the result of (i) an increased interest rate, due to the Company's increased Total Leverage Ratio (as defined in the Credit Agreement), combined with our debt refinancing in December 2020 at higher interest rates, (ii) an increase in deferred financing costs from those incurred in connection with the Company's amendments to the Credit Agreement since May 31, 2020 combined with our debt refinancing in December 2020, and (iii) an increase in total outstanding debt from $190.3 million as of May 31, 2020 to $193.9 million as of May 30, 2021.
The increase in interest expense during fiscal year 2020, compared to fiscal year 2019, was the result of an increase in total debt from $149.0 million as of May 26, 2019 to $190.3 million as of May 31, 2020. The increase in debt was primarily due to additional borrowings to fund working capital requirements and new equipment purchases during fiscal year 2020.

28

Table of Contents
Loss on Debt Refinancing

The loss on debt refinancing was due to a write-off of unamortized debt issuance costs in connection with the Company refinancing its debt in December 2020.
Other Income (Expense)
The decrease in other income (expense) for fiscal year 2021 was primarily the result of the change in fair value of the Company’s previously held investment in Windset, which decreased $11.8 million for the twelve months ended May 30, 2021, compared to a decrease of $4.2 million for the twelve months ended May 31, 2020.
The decrease in other income (expense) for fiscal year 2020 was a result of the change in the fair value of the Company’s previously held investment in Windset, which decreased $4.2 million for the twelve months ended May 31, 2020, compared to an increase of $1.6 million for the twelve months ended May 26, 2019.

Subsequent to fiscal year end 2021, the Company sold its investment in Windset on June 1, 2021.
Income Tax (Expense) Benefit

The change in income tax (expense) benefit for fiscal year 2021 compared to fiscal year 2020 was primarily due to the Company’s reduction in net loss before income taxes and the Company’s effective tax rate decreasing to 19% in fiscal year 2021 from 26% in fiscal year 2020. The effective tax rate differs for fiscal year 2021 from the statutory federal income tax rate of 21% as a result of several factors, including the Company’s benefit of federal and state research and development credits, and the change in valuation allowance established against federal, California, and other state attributes expected to expire prior to recognition.

The change in income tax (expense) benefit for fiscal year 2020 compared to fiscal year 2019 was primarily due to the decrease in the Company’s profit before income taxes, carryback of net operating losses driven by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), and the benefit of federal and state research and development credits.

Liquidity and Capital Resources
As of May 30, 2021, the Company had cash and cash equivalents of $1.3 million, a net increase of $0.9 million from $0.4 million at May 31, 2020.

Cash Flows from Operating Activities 

Net cash provided by operating activities during fiscal year 2021 was $15.0 million compared to the use of $17.0 million of cash from operating activities during fiscal year 2020. The primary sources of net cash provided by operating activities during fiscal year 2021 were from (1) Lifecore’s net income from continuing operations and (2) a net decrease of $8.9 million in working capital. These sources of cash were offset by Curation Foods and Other operating loss from continuing operations.

The primary factors for the decrease in working capital during fiscal year 2021 were (1) a $7.9 million decrease in prepaid expenses and other current assets primarily due to the Company’s receipt of income tax refunds related to fiscal year 2020’s net loss from continuing operations before taxes and carrybacks of net operating losses related to the CARES Act, (2) a $5.8 million decrease in accounts receivable driven by an decrease in Curation Foods’ revenues in the fourth quarter of fiscal year 2021 compared to fiscal year 2020 coupled with timing of customer payments, and (3) a $3.3 million increase in accrued compensation primarily related to the amount and timing of bonus payments and deferred payroll taxes under the CARES Act. These decreases in working capital during 2021 were partially offset by (1) a $6.0 million decrease in accounts payable primarily due to the timing of cash payments and (2) a $3.4 million increase in inventory primarily to support the planned sales growth at Lifecore.

Cash Flows from Investing Activities

Net cash used in investing activities for fiscal year 2021 was $10.9 million compared to $23.9 million for the same period last year. The use of cash in investing activities for fiscal year 2021, was primarily due to the purchase of $23.8 million of equipment to support the growth of the Company’s Lifecore and Curation Foods businesses, partially offset by the receipt of $12.9 million primarily related to the sale of Curation Foods’ factories in Hanover, Pennsylvania and Ontario, California.
29

Table of Contents

Cash Flows from Financing Activities

Net cash used in financing activities for fiscal year 2021 was $3.4 million compared to $40.0 million of net cash provided by financing activities for the same period last year. The net cash used by financing activities during fiscal year 2021 was primarily due to the $48.4 million net pay down on the Company’s revolving line of credit and $10.5 million of debt issuance costs incurred to refinance the Company's term loan and revolving line of credit. The net cash used by these financing activities was primarily offset by the $55.9 million of net cash received from the increase in the Company’s refinanced term loan.

Capital Expenditures

Landec incurred $23.8 million of capital expenditures during fiscal year 2021, which were primarily represented by continued facility modifications and expansions and equipment purchases intended to increase production capacity to support the growth and increased production efficiency of the Lifecore and Curation Foods businesses. Capital expenditures incurred during fiscal year 2020 were $26.7 million.

Debt

On September 23, 2016, the Company entered into a Credit Agreement with JPMorgan, BMO Harris Bank N.A. ("BMO"), and City National Bank, as lenders (collectively, the “Lenders”), and JPMorgan as administrative agent, pursuant to which the Lenders provided the Company with a $100.0 million revolving line of credit (the “Revolver”) and a $50.0 million term loan facility (the “Term Loan”), guaranteed by each of the Company’s direct and indirect subsidiaries and secured by substantially all of the Company’s assets, with the exception of the Company’s investment in Windset.
On November 30, 2018, the Company entered into the Fourth Amendment to the Credit Agreement, which increased the Term Loan to $100.0 million and the Revolver to $105.0 million.
On October 25, 2019, the Company entered into the Sixth Amendment to the Credit Agreement, which increased the Term Loan to $120.0 million and decreased the revolver to $100.0 million. Both the Revolver and the Term Loan mature on October 25, 2022, with the Term Loan requiring quarterly principal payments of $3.0 million and the remainder continuing to be due at maturity.
On March 19, 2020, the Company entered into the Seventh Amendment to the Credit Agreement (the “Seventh Amendment”), which among other changes, retroactively increased the maximum Total Leverage Ratio (as defined in the Credit Agreement as the ratio of the Company’s total indebtedness on such date to the Company’s consolidated EBITDA for the period of four consecutive fiscal quarters ended on or most recently prior to such date) to 5.75 to 1.00 for the fiscal quarter ended February 23, 2020, which decreases back to 5.00 to 1.00 for the fiscal quarter ending May 31, 2020. The maximum Total Leverage Ratio thereafter decreases by 25 basis points each subsequent fiscal quarter thereafter, until it reaches 3.50 for the fiscal quarter ending November 28, 2021, and then remains fixed through maturity. The Seventh Amendment also introduced additional financial covenants that remain in effect through May 31, 2020, including minimum cumulative monthly Unadjusted EBITDA thresholds and maximum capital expenditures, as well as additional reporting requirements and frequencies. Interest on both the Revolver and the Term Loan continues to be based upon the Company’s Total Leverage Ratio, at a per annum rate of either (i) the prime rate plus a spread of between 0.25% and 3.00% or (ii) the Eurodollar rate plus a spread of between 1.25% and 4.00%.
On July 15, 2020, the Company entered into the Eighth Amendment to the Credit Agreement (the “Eighth Amendment”), which among other things, (i) modified the definition of EBITDA to increase the limit on permitted exclusions for certain unusual, extraordinary or one-time cash items for each fiscal quarter ending on or after February 28, 2021, to a maximum of 20% of EBITDA, and (ii) restricted the Company from making Capital Expenditures over certain thresholds. Interest continued to be based on the Company’s Total Leverage Ratio, at a revised per annum Applicable Rate of either (i) the prime rate plus a spread of between 0.75% and 3.50% or (ii) the Eurodollar rate plus a spread of between 1.75% and 4.50%, plus, in each case, a commitment fee, as applicable, of between 0.15% and 0.55%, as further described in the Eighth Amendment.
On December 31, 2020, the Company refinanced its existing Term Loan and Revolver by entering into two separate Credit Agreements (the "New Credit Agreements") with BMO and Goldman Sachs Specialty Lending Group, L.P. (“Goldman”) and Guggenheim Credit Services, LLC ("Guggenheim"), as lenders (collectively, the “Refinance Lenders”). Pursuant to the credit agreement related to the revolving credit facility, BMO has provided the Company, Curation Foods and Lifecore, as co-borrowers, with an up to $75.0 million revolving line of credit (the “Refinance Revolver”) and serves as administrative agent of the Refinance Revolver. Pursuant to the credit agreement related to the term loan, Goldman and Guggenheim have provided the Company, Curation Foods and Lifecore, as co-borrowers, with an up to $170.0 million term loan facility (split equally between
30

Table of Contents
Goldman and Guggenheim) (the “Refinance Term Loan”) and Goldman serves as administrative agent of the Refinance Term Loan. The Refinance Revolver and Refinance Term Loan are guaranteed, and secured by, substantially all of the Company’s and the Company's direct and indirect subsidiaries' assets.
The Refinance Term Loan matures on December 31, 2025. The Refinance Revolver matures on December 31, 2025 or, if the Refinance Term Loan remains outstanding on such date, ninety (90) days prior to the maturity date of the Refinance Term Loan (on October 2, 2025).
The Refinance Term Loan provides for principal payments by the Company of 5% per annum, payable quarterly in arrears in equal installments, commencing on March 30, 2023, with the remainder due at maturity.
Interest on the Refinance Revolver is based upon the Company’s average availability, at a per annum rate of either (i) LIBOR rate plus a spread of between 2.00% and 2.50% or (ii) base rate plus a spread of between 1.00% and 1.50%, plus a commitment fee, as applicable, of 0.375%. Interest on the Refinance Term Loan is at a per annum rate based on either (i) the base rate plus a spread of 7.50% or (ii) the LIBOR rate plus a spread of 8.50%.
The New Credit Agreements provide the Company the right to increase the revolver commitments under the Refinance Revolver, subject to the satisfaction of certain conditions (including consent from BMO), by obtaining additional commitments from either BMO or another lending institution at an amount of up to $15.0 million.

The New Credit Agreements contain customary financial covenants and events of default under which the obligations thereunder could be accelerated and/or the interest rate increased in specified circumstances.

In connection with the New Credit Agreements, the Company incurred debt issuance costs from the lender and third-parties of $10.2 million.

Concurrent with the close of the New Credit Agreements, the Company repaid all outstanding borrowings under the current Credit Agreement, and terminated the Credit Agreement. In connection with the repayment of borrowings under the Credit Agreement, the Company recognized a loss in fiscal year 2021 of $1.1 million, as a result of the non-cash write-off of unamortized debt issuance costs related to the refinancing under the New Credit Agreements.

As of May 30, 2021, (i) $29.0 million was outstanding on the Refinance Revolver, at an interest rate of 3.0%, (ii) $170.0 million was outstanding on the Refinance Term Loan, at an interest rate of 9.5%, and (iii) the Company was in compliance with all financial covenants and had no events of default under the New Credit Agreements.
Contractual Obligations
The Company’s material contractual obligations for the next five years and thereafter as of May 30, 2021, are as follows:
(in thousands)
Due in Fiscal Year Ended May
ObligationTotal20222023202420252026Thereafter
Debt obligations$199,000 $— $2,125 $8,469 $8,422 $179,984 $— 
Interest payments associated with debt obligations 73,400 17,197 17,178 16,860 13,207 8,958 — 
Finance leases3,974 466 3,497 — — 
Operating leases32,758 4,850 4,052 3,263 2,502 2,015 16,076 
Purchase commitments75,441 20,344 6,179 5,985 5,604 5,604 31,725 
Total$384,573 $42,857 $33,031 $34,586 $29,737 $196,561 $47,801 

Debt obligations reflect the principal amounts outstanding on the Term Loan and the Revolver at fiscal year-end. The interest payment amounts above are based on principal amounts and contractual rates at fiscal year-end. See “Note 7 – Debt” in the notes to our consolidated financial statements for further information on the Company’s loans.

The Company’s future capital requirements will depend on numerous factors, including the progress of its research and development programs; the continued development of marketing, sales and distribution capabilities; the ability of the Company to establish and maintain new licensing arrangements; the costs associated with employment-related claims; any decision to pursue additional acquisition opportunities; weather conditions that can affect the supply and price of produce, the timing and amount, if any, of payments received under licensing and research and development agreements; the costs involved in preparing, filing,
31

Table of Contents
prosecuting, defending, and enforcing intellectual property rights; the ability to comply with regulatory requirements; the emergence of competitive technology and market forces; the effectiveness of product commercialization activities and arrangements; and other factors. If the Company’s currently available funds, together with the internally generated cash flow from operations are not sufficient to satisfy its capital needs, the Company would be required to seek additional funding through other arrangements with collaborative partners, additional bank borrowings and public or private sales of its securities. There can be no assurance that additional funds, if required, will be available to the Company on favorable terms, if at all.
The Company believes that its cash from operations, along with existing cash and cash equivalents and availability under its line of credit will be sufficient to finance its operational and capital requirements for at least the next twelve months.
Off-Balance Sheet Arrangements
The Company is not a party to any agreements with, or commitments to, any special purpose entities that would constitute material off-balance sheet financing.

Item 7A.    Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Exposure
Our net interest expense is sensitive to changes in the general level of interest rates. In this regard, changes in interest rates will affect our net interest expense, as well as the fair value of our debt.
On December 31, 2020, the Company refinanced its existing Term Loan and Revolver by entering into two separate Credit Agreements (the "New Credit Agreements") with BMO and Goldman Sachs Specialty Lending Group, L.P. (“Goldman”) and Guggenheim Credit Services, LLC ("Guggenheim"), as lenders (collectively, the “Refinance Lenders”). Pursuant to the credit agreement related to the revolving credit facility, BMO has provided the Company, Curation Foods and Lifecore, as co-borrowers, with an up to $75.0 million revolving line of credit (the “Refinance Revolver”) and serves as administrative agent of the Refinance Revolver. Pursuant to the credit agreement related to the term loan, Goldman and Guggenheim have provided the Company, Curation Foods and Lifecore, as co-borrowers, with an up to $170.0 million term loan facility (split equally between Goldman and Guggenheim) (the “Refinance Term Loan”) and Goldman serves as administrative agent of the Refinance Term Loan. The Refinance Revolver and Refinance Term Loan are guaranteed, and secured by, substantially all of the Company’s and the Company's direct and indirect subsidiaries' assets.
Interest on the Refinance Revolver is based upon the Company’s average availability, at a per annum rate of either (i) LIBOR rate plus a spread of between 2.00% and 2.50% or (ii) base rate plus a spread of between 1.00% and 1.50%, plus a commitment fee, as applicable, of 0.375%. Interest on the Refinance Term Loan is at a per annum rate based on either (i) the base rate plus a spread of 7.50% or (ii) the LIBOR rate plus a spread of 8.50%.

A hypothetical 100 basis point increase or decrease in weighted average interest rates under our Refinance Revolver, based upon the face value of such instruments, would increase our interest expense by approximately $0.3 million over a twelve-month period.
Foreign Currency Exposure
Our Mexican-based operations transacts a portion of the business in Mexican pesos. Funds are transferred by our corporate office to Mexico to satisfy local Mexican cash needs. We do not currently use derivative instruments to hedge fluctuations in the Mexican peso to U.S. dollar exchange rates. Total impact from foreign currency translation is not significant.

Item 8.    Financial Statements and Supplementary Data
See Item 15 of Part IV of this report.

Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
32

Table of Contents

Item 9A.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of May 30, 2021, our management evaluated, with participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective in ensuring that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission, and are effective in providing reasonable assurance that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended). In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control - Integrated Framework (2013 Framework). Our management has concluded that we maintained effective internal control over financial reporting as of May 30, 2021.
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.
Our independent registered public accounting firm, Ernst & Young LLP, has issued an audit report on our internal control over financial reporting, which appears below.
Changes in Internal Controls over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended May 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B.    Other Information
None
33

Table of Contents
PART III

Item 10.    Directors, Executive Officers and Corporate Governance
This information required by this item will be contained in the Registrant’s definitive proxy statement or in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission not later than September 27, 2021 (120 days after the Registrant’s fiscal year end covered by this Annual Report on Form 10-K) and is incorporated herein by reference.

Item 11.    Executive Compensation
This information required by this item will be contained in the Registrant’s definitive proxy statement or in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission not later than September 27, 2021 (120 days after the Registrant’s fiscal year end covered by this Annual Report on Form 10-K) and is incorporated herein by reference.

Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
This information required by this item will be contained in the Registrant’s definitive proxy statement or in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission not later than September 27, 2021 (120 days after the Registrant’s fiscal year end covered by this Annual Report on Form 10-K) and is incorporated herein by reference.

Item 13.    Certain Relationships and Related Transactions and Director Independence
This information required by this item will be contained in the Registrant’s definitive proxy statement or in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission not later than September 27, 2021 (120 days after the Registrant’s fiscal year end covered by this Annual Report on Form 10-K) and is incorporated herein by reference.

Item 14.    Principal Accountant Fees and Services
This information required by this item will be contained in the Registrant’s definitive proxy statement or in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission not later than September 27, 2021 (120 days after the Registrant’s fiscal year end covered by this Annual Report on Form 10-K) and is incorporated herein by reference.
34

Table of Contents
PART IV

Item 15.    Exhibits and Financial Statement Schedules

(a)1.Consolidated Financial Statements of Landec Corporation 
 Page
 
 
 
 
 
 
 
 2.All schedules provided for in the applicable accounting regulations of the Securities and Exchange Commission have been omitted since they pertain to items which do not appear in the financial statements of Landec Corporation and its subsidiaries or to items which are not significant or to items as to which the required disclosures have been made elsewhere in the financial statements and supplementary notes and such schedules.
 3.
 The exhibits listed in the accompanying Index of Exhibits are filed or incorporated by reference as part of this report.

35

Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors of Landec Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Landec Corporation and subsidiaries (the Company) as of May 30, 2021 and May 31, 2020, and the related consolidated statements of operations, comprehensive (loss) income, stockholders' equity and cash flows for each of the three years in the period ended May 30, 2021, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at May 30, 2021 and May 31, 2020, and the results of its operations and its cash flows for each of the three years in the period ended May 30, 2021, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of May 30, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated July 29, 2021 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Valuation of Goodwill and Trademarks/tradenames with Indefinite lives
Description of the Matter
At May 30, 2021, the Company’s goodwill was $69.3 million and trademarks/tradenames with indefinite lives was $25.3 million. The carrying values of the Company’s Yucatan reporting unit’s goodwill and trademarks/tradenames with indefinite lives were $20.0 million and $12.4 million, respectively at May 30, 2021. As discussed in Note 1 of the consolidated financial statements, goodwill and trademarks/tradenames with indefinite lives are assessed by the Company’s management for impairment at least annually, in the fiscal fourth quarter, unless there are indications of impairment at other points throughout the year. Goodwill is tested for impairment at the reporting unit level. The Company measured the fair value of the goodwill using an income approach and the fair value of trademarks/tradenames using a royalty savings method.

36

Table of Contents
Auditing the Company’s annual impairment test related to the Yucatan reporting unit’s goodwill and trademarks/tradenames with indefinite lives is complex and highly judgmental and required the involvement of our valuation specialist due to the significant judgment in estimating their fair values. In particular, the fair value estimate of the Yucatan reporting unit’s goodwill is sensitive to assumptions such as net sales growth rates, gross margins and discount rate. The Yucatan reporting unit’s trademarks/tradenames with indefinite lives are sensitive to assumptions such as net sales growth rates, royalty rate and discount rate. These assumptions are forward-looking and sensitive to and affected by expected future market or economic conditions and industry and company-specific qualitative factors.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s impairment review process related to the goodwill and trademarks/tradenames with indefinite lives. This included evaluating controls over the Company’s budgetary and forecasting process used to develop the estimated future earnings and cash flows used in estimating the fair value of the Yucatan reporting unit and trademarks/tradenames with indefinite lives. We also tested controls over management’s review of the data used in their valuation models and review of the significant assumptions described above.

To test the estimated fair value of the Yucatan reporting unit and trademarks/tradenames with indefinite lives, we performed audit procedures that included, among others, assessing the methodologies, testing the significant assumptions discussed above used to develop the estimates of future earnings and cash flows and testing the completeness and accuracy of the underlying data. We compared the significant assumptions used by management to current industry and economic trends, the Company’s historical results and other guideline companies within the same industry and evaluated how changes in the Company’s business may affect the significant assumptions. We assessed the historical accuracy of management’s estimates and performed sensitivity analyses of significant assumptions to evaluate the change in the fair value of the Yucatan reporting unit and trademarks/tradenames with indefinite lives resulting from changes in these assumptions. We involved our valuation specialists to assist in reviewing the valuation methodology and the royalty and discount rate assumptions. In addition, for goodwill we also tested the Company’s calculation of implied multiples of the reporting units, compared them to guideline companies and evaluated the resulting premium. For trademarks/tradenames with indefinite lives, where applicable, we also assessed whether the assumptions used were consistent with those used in the goodwill impairment review process.

/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2008.
San Francisco, California
July 29, 2021
37

Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of Landec Corporation
Opinion on Internal Control over Financial Reporting
We have audited Landec Corporation and subsidiaries’ internal control over financial reporting as of May 30, 2021, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Landec Corporation and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of May 30, 2021, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of May 30, 2021 and May 31, 2020, and the related consolidated statements of operations, comprehensive (loss) income, stockholders’ equity and cash flows for each of the three years in the period ended May 30, 2021, and the related notes and our report dated July 29, 2021 expressed an unqualified opinion thereon.

Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP
San Francisco, California
July 29, 2021
38

Table of Contents

LANDEC CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
 May 30, 2021May 31, 2020
ASSETS 
Current Assets: 
Cash and cash equivalents$1,295 $360 
Accounts receivable, less allowance for credit losses70,013 76,206 
Inventories69,663 66,311 
Prepaid expenses and other current assets7,350 14,230 
Total Current Assets148,321 157,107 
Investment in non-public company, fair value45,100 56,900 
Property and equipment, net179,559 192,338 
Operating lease right-of-use assets20,827 25,321 
Goodwill69,386 69,386 
Trademarks/tradenames, net25,328 25,328 
Customer relationships, net10,792 12,777 
Other assets3,611 2,156 
Total Assets$502,924 $541,313 
LIABILITIES AND STOCKHOLDERS’ EQUITY 
Current Liabilities: 
Accounts payable$47,569 $51,647 
Accrued compensation12,304 9,034 
Other accrued liabilities7,996 9,978 
Current portion of lease liabilities3,889 4,423 
Deferred revenue1,130 352 
Line of credit29,000 77,400 
Current portion of long-term debt, net 11,554 
Total Current Liabilities101,888 164,388 
Long-term debt, net164,902 101,363 
Long-term lease liabilities23,611 26,378 
Deferred taxes, net6,140 13,588 
Other non-current liabilities3,599 4,552 
Total Liabilities300,140 310,269 
Stockholders’ Equity: 
Common stock, $0.001 par value; 50,000 shares authorized; 29,333 and 29,224 shares issued and outstanding at May 30, 2021 and May 31, 2020, respectively
29 29 
Additional paid-in capital165,533 162,578 
Retained earnings38,580 71,245 
Accumulated other comprehensive loss(1,358)(2,808)
Total Stockholders’ Equity202,784 231,044 
Total Liabilities and Stockholders’ Equity$502,924 $541,313 
See accompanying notes to the consolidated financial statements.
39

Table of Contents
LANDEC CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
 Year Ended
 May 30, 2021May 31, 2020May 26, 2019
Product sales$544,161 $590,366 $557,559 
Cost of product sales462,687 515,378 476,556 
Gross profit81,474 74,988 81,003 
Operating costs and expenses:   
Research and development10,222 11,099 11,466 
Selling, general and administrative65,364 72,188 62,062 
Impairment of goodwill and intangible assets 12,953 2,000 
Legal settlement charge1,763   
Restructuring costs17,621 17,285  
Total operating costs and expenses94,970 113,525 75,528 
Operating (loss) income(13,496)(38,537)5,475 
Dividend income1,125 1,125 1,650 
Interest income48 103 145 
Interest expense, net(15,344)(9,603)(5,230)
Loss on debt refinancing(1,110)  
Other (expense) income, net(11,689)(4,395)1,600 
Net (loss) income from continuing operations before taxes(40,466)(51,307)3,640 
Income tax benefit (expense)7,801 13,116 (1,518)
Net (loss) income from continuing operations(32,665)(38,191)2,122 
Discontinued operations:   
Loss from discontinued operations  (2,238)
Income tax benefit  527 
Loss from discontinued operations, net of tax  (1,711)
Net (loss) income(32,665)(38,191)411 
Basic net (loss) income per share:   
(Loss) income from continuing operations$(1.12)$(1.31)$0.07 
Loss from discontinued operations  (0.06)
Total basic net (loss) income per share$(1.12)$(1.31)$0.01 
Diluted net (loss) income per share:   
(Loss) income from continuing operations$(1.12)$(1.31)$0.07 
(Loss) from discontinued operations  (0.06)
Total diluted net (loss) income per share$(1.12)$(1.31)$0.01 
Shares used in per share computation:
Basic29,294 29,162 28,359 
Diluted29,294 29,162 28,607 
See accompanying notes to the consolidated financial statements.
40

Table of Contents
LANDEC CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(In thousands)
 Year Ended
 May 30, 2021May 31, 2020May 26, 2019
Net (loss) income$(32,665)$(38,191)$411 
Other comprehensive (loss) income, net of tax:   
Net unrealized gains (losses) on interest rate swaps, (net of tax effect of ($445), $878, and $282)
1,450 (2,872)(1,084)
Other comprehensive (loss) income, net of tax1,450 (2,872)(1,084)
Total comprehensive loss$(31,215)$(41,063)$(673)
See accompanying notes to the consolidated financial statements.
41

Table of Contents
LANDEC CORPORATION